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ABSTRACT 
 
Breast cancer is the first human carcinoma for which a putative cancer stem cell 
subpopulation (BCSC) has been isolated with the CD44
+
/CD24
-/low
 phenotype. However, 
several studies have highlighted that CD44
+
/CD24
-/low
 cannot be considered the universal 
marker phenotype of BCSCs. The aim of this thesis is to identify novel BCSCs markers. We 
focused our work on the basal-like breast cancers that seem to derive from a developmental 
stage of mammary epithelial cell that is different from the primitive stem cell, namely the 
luminal progenitor. 
In the first part of the present thesis we have characterized breast cancer cell lines resembling 
different tumor molecular subtypes, by using polychromatic flow cytometry. These analyses 
led us to hypothesize that the basal-A cell line HCC1937 could contain a putative 
CD24
+
CD338
+
 CSC subpopulation. We have next found that CD338 overexpressing cells, 
namely CD338
bright
, overlap, almost completely, with the side population in the HCC1937 cell 
line. Since side population is a property of stem/progenitor cells, this result suggested a key 
role of CD338 in determining stem-like properties of HCC1937 cell line.  
To test this hypothesis, we next isolated the putative BCSCs, on the base of CD24 and CD338 
expression, and we further studied them to explore their stem-like and tumorigenic properties. 
We found that CD24
hi 
cells display a higher mammosphere forming efficiency than CD24
-
 
cells and, among CD24
hi 
cells, CD338 overexpressing cells are able to form mammospheres 
with higher efficiency than CD338
-
 cells. This result confirmed a relevant role of CD338 in 
stem-like properties of HCC1937 cell line. Furthermore, the soft-agar colony assays revealed 
that CD338 positive cells are transformed in contrary to the negative ones. We next evaluated 
the tumorigenic potential of the different CD338 sorted subpopulations and we found that 
cells expressing CD338 at an intermediate level, namely CD338
low
, were the most 
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tumorigenic ones. Furthermore, the analysis of CD338
bright
 and CD338
low
 sorted sub-
populations, after their growth in culture for several weeks, revealed that CD338
bright
 
population is able to divide asymmetrically giving rise to its CD338
low
 progeny which, in 
contrast, is not able to divide asymmetrically. This result suggested that CD338
bright
 
population could constitute the most immature population and its CD338
low
 progeny the more 
differentiated progenitor cells. Taken together, these results strongly support the presence in 
the HCC1937 cell line of a putative BCSC subpopulation overexpressing CD338 and bearing 
the phenotype CD44
+
CD24
+
CD338
bright
, i.e. an antigenic combination different from the 
classical CD44
+
/CD24
-/low
.   
Concurrently to the study of breast cancer cell lines, a complementary work was carried out to 
standardize the flow-cytomertic methods to study primary cultures established from human 
breast cancer tissues. This work will be subsequently used to isolate and study the 
CD44
+
CD24
+
CD338
bright
 CSC population from human breast cancer tissues. In this study, we 
have also tried to determine whether patient-derived breast cancer cell cultures maintain the 
cellular heterogeneity of primary tissues and may therefore be used for in vitro modeling of 
breast cancer subtypes. To this aim, we used a much larger vocabulary of surface markers 
than those used in previous studies to characterize primary cultures. Most of surface antigens 
analyzed were heterogeneously expressed. On the other hand, breast cancer cell cultures 
displayed concomitant high expression of the basal marker CD10/CALLA and low expression 
of CD326/EpCAM. Furthermore, we found that they express CK5, SMA and vimentin, and 
are weakly positive for CK19 and CK18-negative. Our results, while confirming that in vitro 
culturing of breast cancer cells reduces luminal lineage-type of cells, indicate the increased 
propensity for the selection of myoepithelial/basal breast cancer cells. Furthermore, we have 
demonstrated that breast cancer cell cultures preserve inter-tumor heterogeneity and express 
stem/progenitor markers that can be identified, quantified and categorized by flow cytometry. 
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I. INTRODUCTION 
 
1.1 The Cancer Stem Cell theory  
1.1.1  Two general models of heterogeneity in solid cancers 
It is well established that tumors are proliferatively heterogeneous. Particularly, cancer cells 
within a single tumor exist in multiple states of differentiation and only a subfraction of tumor 
cells is able to self-renew either in vitro or in in vivo xenograft models, by generating tumors 
with serial transplantations. Two theories have been proposed to explain this (Figure 1.1a). 
The “stochastic” theory suggests that cancers arise from waves of genetic and epigenetic 
mutations that affect the survival and reproduction of cells, providing a selective advantage 
and generating clonal heterogeneity. In contrast, the “cancer stem cell” (CSC) theory holds 
that tumors are organized in a cellular hierarchy in which cancer stem cells (CSCs) are the 
only cells with unlimited proliferation potential and with the capability of driving tumor 
growth and progression. Thus, CSCs can be defined as rare cells within tumors with the 
ability to self-renew and give rise to the phenotypically diverse cancer cell population.  
In contrast to the “stochastic” model of oncogenesis, where transformation results from 
random mutations and subsequent clonal selections, according to the CSC model cancers 
would originate from the malignant transformation of a stem or progenitor cells through the 
deregulation of the normally tightly regulated self-renewal program or from transformation of 
committed cells through dedifferentiation of mature cells that gain a self-renewal potential. 
So, the origin of CSCs is currently elusive and, as a consequence, the term “cancer stem cell” 
is disputed because it is not clear weather normal stem cells are the natural precursors of 
“cancer stem cells”. The origin of CSCs seems to be tissue dependent. As regard breast 
cancer, recent studies have shown that in transformed mammary epithelial cells, induction of 
epithelial-mesenchymal transition (EMT) that is a transition of epithelial cells to a less 
10 
 
differentiated stage, creates populations of cells that are highly enriched for CSCs properties, 
such as tumor-seeding ability, mammosphere formation and stem cell surface marker 
expression (Mani et al., 2008; Morel et al., 2008).  
 
1.1.2 Normal stem cells and cancer stem cells 
Normal stem cells (NSCs) and cancer stem cells share a number of important characteristics. 
Particularly, they both have the capacity of self-renewal and extensive proliferation. In the 
case of tumor cells, this takes the form of self-sufficiency in growth signaling and 
uncontrolled cellular proliferation, whereas for normal stem cells, this is a tightly controlled 
process that occurs during embryogenesis, organogenesis, and maintenance and repair of 
adult tissues. NSCs and CSCs also share the ability to differentiate, giving rise to their 
progenity in tissue and to tumor heterogeneity, respectively. Moreover, both cell types have a 
resistance to environmental toxins, chemotherapeutic and radiation agents, often as a result of 
multidrug resistance (MDR) via expression of ABC (ATP-Binding Cassette) family of 
transporter proteins. Stem cells and tumor cells also share the characteristic of being able to 
survive in anchorage independent conditions (resistence to anoikis), leading to migration and 
homing for stem cells and potentially to metastatic disease for tumor and cancer stem cells. 
Finally, both cell types are long-lived with active anti-apoptotic pathways and telomerase 
activity. The longevity of normal stem cells increases the risk of these cells, over a lifetime, to 
acquire the multiple genetic mutations necessary for tumorigenesis. This would lead to 
consider normal stem cells as appropriate candidates for tumor initiating but, on the other 
hand, the slow-cycling property of stem cells is not in agreement with this consideration, 
since DNA replication is likely a prerequisite for mutation. 
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1.1.3  Implication of the CSC theory in cancer treatment 
The CSC theory has implications in cancer treatment. Current anticancer therapy is effective 
at debulking the tumor mass but treatment effects are transient, with often occurring tumor 
relapse and metastatic disease. A possible explication for the failure of existing therapies is 
that they fail to kill cancer stem cells (Figure 1.1b). As mentioned before, normal stem cells 
from various tissues tend to be more resistant to chemotherapeutics than mature cell types 
from the same tissues (Harrison and Lerner 1991). One of the reasons that could explain this, 
is that stem cells express high levels of anti-apoptotic proteins (Feuerhake et al., 2000) and 
ABC transporter proteins (Zhou et al., 2001). Also cancer stem cells seem to overexpress 
transporter proteins and this could explain that these cells would be more resistant to 
chemotherapeutics than committed/differentiated tumor cells with limited proliferative 
potential. Even therapies that cause complete regression of tumors might spare enough cancer 
stem cells to allow regrowth of the tumors. Targeting differentiated as well as quiescent tumor 
stem cells is a prerequisite for therapy to be efficient. On the other hand, it is noteworthy to 
consider the recent emerging possibility of the existence of an equilibrium between CSCs and 
non-CSCs within tumors. In particular, whereas CSCs can differentiate into non-CSCs giving 
rise to the tumor heterogeneity, the reverse process would be possible: non-CSCs, could be 
reprogrammed into CSCs. This phenotypic plasticity has implications for cancer treatment: if 
non-CSCs can give rise to CSCs, therapeutic elimination of CSCs may be followed by their 
regeneration from residual non-CSCs, allowing tumor regrowth and clinical relapse. 
Therefore, optimal therapeutic approaches would target both CSCs and differentiated cells 
(Gupta et al., 2009).   
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1.1.4 Cancer stem cells in solid cancers 
The existence of cancer stem cells was first proven in the context of acute myeloid leukemia 
(AML). In this case, surface markers were used to distinguish AML stem cells (CD34
+
CD38
-
) 
from the remaining AML cells which had limited proliferative potential (Lapidot et al., 1994; 
Bonnet and Dick, 1997).  These cells were found to be the only cells capable of transferring 
AML from human patients to NOD/SCID mice, providing evidence that not all AML cells 
have in vivo clonogenic capacity and only the small subset of CSCs was capable of 
regenerating the cancer. Many groups have extrapolated the CSC hypothesis from the 
haematopoietic system to solid cancers and, although the evidence for CSCs in solid cancers 
is in its infancy compared to the haematopoietic field, the body of supporting data is growing 
rapidly. The first solid CSCs were identified in breast tumors (Al-Hajj et al., 2003), and then 
CSCs were isolated from brain (Singh et al., 2003), colon (O’Brien et al., 2007), melanoma 
(Fang et al., 2005), pancreatic (Hermann et al., 2007), prostate (Collins et al., 2005), ovarian 
(Bapat et al., 2005), lung (Ho et al., 2007) and gastric (Fukuda et al., 2009) cancers. Cells 
with CSC characteristics from human brain tumors (glioblastomas) were first isolated using a 
clonogenic sphere culture technique to produce the so called neurospheres (NS) (Singh et al., 
2003; Singh et al., 2004). These NS cells are highly enriched for cell surface marker CD133 
and nestin (a neural stem cell marker), have a marked capacity for proliferation and self-
renewal and are capable of in vitro differentiation into phenotypes identical to the tumor in 
situ. Breast cancer is the first human carcinoma for which a putative cancer stem cell 
subpopulation (BCSC, breast cancer stem cell) has been isolated by Clarke and colleagues. 
This study showed that in nine breast cancer samples, a minority of cells, bearing the surface 
marker phenotype CD44
+
CD24
-
, were capable of generating tumors in NOD/SCID mice even 
when implanted in low numbers. By contrast, the other cancer cell populations, such as 
CD44
+
CD24
+
, failed to generate tumors even when implanted in high numbers (Al-Hajj et al., 
13 
 
2003). Cell surface antigens  have been used with good success in the haematological system 
to identify stem and progenitor cells, but in solid tumors, such as breast cancers, there is still 
the lack of reliable markers. The relevance of CD44 and CD24 in identifying breast CSCs is 
still matter of debate and, actually, CD44
+
CD24
-/low
 not considered as a universal antigenic 
phenotype for isolation of BCSCs. Furthermore, the use of surface antigens to classify 
different cell subpopulations is actually highly disputed. The major drawback of this 
technique is that there is rarely a marker that is 100% expressed in one population and 
completely lost in the next. Indeed a gradient of expression of cell surface antigens is more 
often detected. As a consequence, cell sorting based on surface antigens allows for enrichment 
rather than isolation of the various sub-populations. 
 
 
 
.  
 
 
 
 
 
 
 
 
 
Figure 1.1. The cancer stem cell theory. (a) Two general models of hete8rogeneity in solid 
cancers; (b) Comparison between conventional therapies and cancer stem cell targeted 
therapies (Reya, 2001). 
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1.2 The human mammary gland and stem cells in normal human breast 
The mammary gland is a compound tubulo-alveolar composed of a series of branched ducts 
that drain sac-like alveoli (lobules) during lactation. In the mouse, the mammary epithelium is 
embedded within a mammary fat pad, whereas in humans, it is embedded within a fibrous and 
fatty connective tissue. The functional units of the human mammary gland are comprised of 
terminal ducts and alveoli, which together form the terminal duct lobular units (TDLUs). 
Collectively, TDLUs form the branches of a greater ductal-lobular system composed of an 
inner layer of polarized luminal cells and an outer layer of myoepithelial cells (Figure 1.2). 
Myoepithelial cells are contractile cells that form a sheath around the ductal network of the 
breast and are characterized by expression of common acute lymphoblastic leukaemia antigen 
(CALLA) also known as CD10 (Gusterson et al., 1986), Thy-1 also known as CD90 
(Gudjonsson et al., 2002), alpha-smooth muscle actin (α-SMA) (Gugliotta et al., 1988), 
vimentin (Guelstein et al., 1988), and cytokeratin (CK) 5 and CK14 (Taylor-Papadimitriou et 
al., 1989). Luminal epithelial cells are cuboidal/columnar cells that line the ducts and alveoli 
and are the cells responsible for milk production during lactation. They are characterized by 
expression of Mucin-1 (MUC-1) also known as CD227 (Petersen et al. 1986), epithelial cell 
adhesion molecule (EpCAM) also known as epithelial surface antigen (ESA) or CD326 
(Latza et al., 1990), and CK7, CK8, CK18, and CK19 as well as estrogen receptor (ER) and 
progesterone receptor (PgR). The adult human breast is composed of 15 to 20 lobes each with 
multiple lobules surrounded by adipose tissue. Additionally, the breast has a system of 
lymphatic vessels responsible for draining breast tissue leading to internal mammary lymph 
nodes and axillary regional lymph nodes. 
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The human breast is a dynamic gland with tissue homeostasis occurring during early 
development, puberty, within menstrual cycles, during pregnancy and lactation, and eventual 
involution during menopause. During periods of pregnancy and lactation, the breast goes 
through further rounds of development with an increase in cell growth and formation from the 
luminal epithelial lineage of functional milk-secreting alveoli. Following these periods and 
again during menopause, there is an involution through apoptosis of the breast tissue. 
Generation and maintenance of the mammary epithelium is hypothesized to be via the 
mammary stem cell (MaSC), which is defined as that cell which can generate both the ductal 
and lobular structures of the mammary gland. (Kordon and Smith, 1998; Stingl et al., 1998). 
Transplantation of a single FACS-isolated MaSC, can reconstitute, a normal mammary gland 
(Stingl et al., 2006: Shackleton et al., 2006). Transplantation studies have an important limit: 
they mimic a regenerative state that in certain circumstances forces stem cells to differentiate 
 
Figure 1.2. Schematic representation of the human mammary gland. 
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into lineages for which they usually do not contribute to under physiological conditions. So, it 
is necessary to develop assays that allow to define the cellular hierarchy of the mammary 
gland during physiological conditions. To this aim, genetic lineage-tracing approaches in 
mice have been recently developed. In this study, it has been demonstrated that the mammary 
gland contains different types of long-lived stem cells. Particularly, Blanpain and colleagues 
have found that the expansion and maintenance of luminal and myoepithelial lineages is 
ensured by the presence of two types of lineage-restricted stem cells, rather than by rare 
multipotent stem cells (Van Keymeulen et al., 2011). The demonstration that the mammary 
gland contains different types of long-lived stem cells, has important implications for the 
study of the origin of breast cancers. 
The study of stem cells within the human mammary epithelium has been much more difficult 
than their mouse counterparts due to the lack of a suitable in vivo xenotransplantation assay. 
The human mammary epithelium in vivo is embedded within an irregular extracellular matrix 
rich in collagen fibers and mammary fibroblasts. In rodents, the extracellular matrix is 
composed primarily of adipocytes. Consequently, human mammary epithelial cells (HMECs) 
fail to recapitulate the ductal-lobular outgrowths when transplanted into cleared fat pads of 
immune-deficient mice, presumably as a result of inappropriate epithelial-stromal interactions 
(Hovey et al., 1999). A solution to circumvent this, is to transplant single cell suspensions of 
HMECs into humanized fat pads (i.e. fat pads pre-inoculated with human mammary 
fibroblasts) or have embedded the HMECs within collagen gels and/or Matrigel and place 
these cells either subcutaneously or under the renal capsule of immune-deficient mice (Yang 
et al., 1994; Stingl et al., 2003; Proia et al., 2006). HMECs transplanted under such 
conditions recapitulate histologically normal looking human mammary epithelium, complete 
with polarized luminal cells, SMA-expressing myoepithelial cells, basal clear cells and small 
light cells (Stingl et al., 2003). The most useful markers for isolating human mammary stem 
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cells are the epithelial cell adhesion molecule (EpCAM/CD326), the α6-integrin/CD49f and, 
to a lesser degree, the luminal cell-specific glycoprotein MUC1/CD227, the common acute 
lymphoblastic leukemia antigen CALLA/CD10 and the GPI-linked glycoprotein Thy-1/CD90 
(Stingl et al., 1998; Stingl et al., 2001; Eirew et al., 2008; Villadsen et al., 2007; Raouf et al., 
2008). EpCAM/CD326 is an epithelial-specific molecule that is expressed at high level by 
luminal cells and at lower level by basal cells; CD49f is an integrin known to participate in 
cell adhesion as well as cell surface mediating signaling and it displays a pattern of expression 
inverse to that of EpCAM (Stingl et al., 1998; Carter et al., 1990). Although both 
EpCAM/CD326 and CD49f are not particularly useful for identifying different subsets of 
HMECs when separately used, when combined they permit a number of distinct cell types to 
be resolved by flow cytometry. MUC1/CD227 is a cell surface glycoprotein expressed by 
most epithelial cells and involved in cell-cell and cell-substrate adhesion. CALLA/CD10 is a 
membrane-associated endopeptidase overexpressed in many neoplastic cell types and 
Thy1/CD90 is a membrane-associated glycoprotein involved in cell adhesion, migration and 
proliferation. In vitro analyses of human mammary epithelial colony-forming cells (Ma-
CFCs) have demonstrated the existence of three distinct progenitors within the human 
mammary epithelium (Figure 1.3): 1) the luminal-restricted progenitors which generate 
colonies that are composed of cells with a luminal cell phenotype (expressing CK8, 18, 19 
and 9). Replating of these colonies in secondary CFC assays reveals that cells of these 
colonies are indeed restricted to a luminal cell fate, since they only form pure luminal cell 
colonies. These luminal restricted progenitors display the phenotype EpCAM/CD326
hi 
CD49f
+ 
MUC1/CD227
+ 
CALLA/CD10
- 
Thy1/CD90
-
 (Stingl et al., 2001; Villadsen et al., 
2007). 2) The bipotent progenitors display a EpCAM/CD326
-/low 
CD49f
high 
MUC1/CD227
- 
CALLA/CD10
+ 
Thy1/CD90
+
 antigenic phenotype. These progenitors generate colonies that 
are characterized by a central core of CK14−CK18+CK19+MUC1+ luminal cells and a 
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peripheral zone of CK14+ basal cells. Single-cell cloning of these progenitors confirms that 
these mixed colonies are clonal in origin (Stingl et al., 2001).  3) The myoepithelial-restricted 
progenitors generate colonies that are composed solely of CK14+CK18−CK19−MUC1− 
basal-like cells. Serial passaging of the colonies generated by bipotent progenitors has 
demonstrated that myoepithelial-restricted progenitors arise from bipotent progenitors. The 
unipotent progenitors, also known as MRUs (Mammary Repopulating Units), have the same 
antigenic phenotype as bipotent progenitors, namely EpCAM/CD326
-/low 
CD49f
high 
MUC1/CD227
- 
CALLA/CD10
+ 
Thy1/CD90
+
, suggesting a basal position within the 
mammary epithelium. However, it is not known whether bipotent progenitors and MRUs 
types represent distinct or overlapping populations within the basal cell population (Stingl et 
al., 2001; Eirew et al., 2008; Raouf et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Model of the differentiation hierarchy within human mammary epithelium. 
 The common progenitor is also referred to as a bipotent progenitor cell (Visvader, 2009).  
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1.3 Breast cancer: a very heterogeneous disease 
Breast cancer is a genetically and clinically heterogeneous disease. Many breast cancer 
classification systems have been developed over many decades and have evolved into a tool 
that is used to aid in treatment and prognosis. The different breast cancer classification 
systems are based on several tumor-intrinsic features that separate breast tumors into multiple 
subtypes, including histological and immunopathological subtypes, molecular subtypes and 
the more recently described functional subtypes based on the identification and 
characterization of tumor initiating cancer stem cells in the different molecular subtypes of 
breast cancer. 
 
1.3.1 Hystological and immunopathological classification of breast cancers 
Based on their overall morphology and structural organization, breast cancers can be 
categorized into in situ carcinoma and invasive or infiltrating carcinoma (Figure 1.4a). In situ 
breast carcinoma is further sub-classified as either ductal or lobular, growth patterns and 
cytological features form the basis to distinguish between the two types. In situ ductal 
carcinoma (DCIS) is considerably more common than in situ lobular carcinoma (LCIS) and 
includes a heterogeneous group of tumors. Particularly, DCIS has traditionally been further 
sub-classified on the basis of the architectural features of the tumor which has given rise to 
five well recognized subtypes: Comedo, Cribiform, Micropapillary, Papillary and Solid 
(Connolly et al., 2004; Figure 1.4a). Similar to in situ carcinomas, invasive carcinomas are a 
heterogeneous group of tumors differentiated into histological subtypes. The major invasive 
tumor types include infiltrating ductal carcinoma (IDC) (Figure 1.4b), invasive lobular 
(Figure 1.4c), ductal/lobular, mucinous (colloid), tubular, medullary and papillary 
carcinomas. Among these tumor types, IDC is, by far, the most common subtype accounting 
for 70–80% of all invasive lesions (Li et al., 2005). IDC is further sub-classified as either 
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well-differentiated (grade 1), moderately differentiated (grade 2) or poorly differentiated 
(grade 3) based on the levels of nuclear pleomorphism, glandular/tubule formation and 
mitotic index (Figure 1.4a). While this classification scheme has been a valuable tool for 
several decades, it relies solely on histology without using newer molecular markers that have 
a proven prognostic significance.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Hystological subtypes of breast cancer. (a) Hystolagical classification of breast 
cancer (Malhotra et al.,  2010). (b,c) Schematic representation of invasive ductal carcinoma 
(IDC, b) and invasive lobular carcinoma (ILC, c). 
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In light of surgical advances leading to breast-conserving therapy, it has become necessary to 
more accurately stratify patients based on relative risk of recurrence or progression. These 
demands have led to the generation of several newer classification systems that incorporate 
specific markers such as estrogen receptor (ER), progesterone receptor (PR or PgR) and 
human epidermal receptor 2 (HER2/ErbB2). In contrast to DCIS, where the use of molecular 
markers is still debated, the utility of ER, PR and HER2/neu is well accepted for IDC and it is 
recommended that their status be determined on all invasive carcinomas. The status of these 
markers helps in determining which patients are likely to respond to targeted therapies 
(Malhotra et al., 2010). In particular, the ER status is used to identify tumors that may 
respond to anti-estrogen (endocrine) therapy, including ER antagonists or aromatase 
inhibitors, which target ER-dependent signaling (Jordan et al., 2007). The PR status, 
generally correlated with the ER status, has less clinical significance. However, the PR status 
does not appear to predict relative benefit from specific types of endocrine therapy (Bartlett et 
al., 2011), and overall, ER+/PR+ cases may not receive additional benefit from endocrine 
therapy compared with ER+/PR– cases (Stendhal et al., 2006). HER2+ cases are treated with 
targeted therapies such as the monoclonal antibody trastuzumab, which binds to HER2, 
mediates antibody-dependent cytotoxicity, and disrupts HER2-dependent signaling (Junttila et 
al., 2009). There is currently no standard targeted therapy for cases assessed as ER– and 
HER– by IHC (immunohistochemistry), although this represents an intensive area of research. 
Thus, combinations of these markers allow for the assignment of individual cases to specific 
categories, namely ER+ (ER+/HER2–), HER2+ (ER–/HER2+), triple negative (TN or TPN; 
ER–/PR–/HER2–), and triple positive (ER+/PR+/HER2+). From a prognostic point of view, 
ER+ tumors exhibit the best overall outcome, whereas HER2+ tumors, previously associated 
with poor outcome, now exhibit an improved overall outcome, after the advent of HER2-
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targeted therapy (Smith et al., 2007). TN tumors, on the other hand, are linked to the worst 
prognosis among the subtypes (Nishimura et al., 2008). 
 
1.3.2 Molecular breast cancer subtypes  
Over the past decade, the advent of high-throughput/high-content microarray-based gene 
expression profiling technologies has facilitated large-scale studies of breast cancer cohorts, 
leading to the identification of multiple molecular subtypes of breast cancers (Figure 1.5). 
Studies by Perou and colleagues described five molecular subtypes defined by distinct 
transcriptional signatures: basal-like, ErbB2+, normal breast like, luminal subtype A and 
luminal subtype B (Sorlie et al., 2003; Perou et al., 2000; Sorlie et al., 2001).  More recently, 
a new subtype classified as “claudin low” has also been identified (Herschkowitz et al., 2007; 
Prat et al., 2010). Molecular subtypes defined by Perou and colleagues partially recapitulate 
the immunopathological classes, while adding an additional level of detail. Two luminal 
subtypes (A and B) contain principally ER+ cases and are distinguished by the presence of 
genes regulated by the ER signaling pathway. The luminal A subtype is associated with 
higher levels of ESR1 (estrogen receptor gene 1), ER, and ER-regulated genes, decreased 
proliferation and improved overall outcome (Sorlie et al., 2001; Perou et al., 1999; Perreard et 
al., 2006). Luminal B tumors appear to exhibit decreased levels of ESR1, ER, and ER-
regulated genes as well as increased proliferation and relatively worse prognosis. Thus, this 
molecular classification was able to stratify the ER+ population into several subtypes that 
demonstrated a difference in patient survival. This is significant because, even though clinical 
assessment of IDC utilizes ER, PR and ErbB2 status, these markers did not allow separation 
of the two distinct ER+ subtypes (i.e., Luminal A and Luminal B) that have very different 
clinical outcomes. Three molecular subtypes contain predominantly ER– cases (Perou et al., 
2000): 1) the molecular ErbB2+ subtype generally overlaps with IHC-defined HER2+ tumors 
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(ER-/HER2-) (Perou et al., 2000); the basal-like subtype broadly corresponds to the TN (ER–
/PR–/HER2–) cohort (Nielsen et al., 2004); 3) the claudin-low subtype linked to metaplastic 
breast cancers and high risk of recurrence, which shows similarity to stem cell-linked and 
epithelial to mesenchymal transition-linked (EMT-linked) signatures (Hennessy et al., 2009). 
Finally, the normal-like subtype, as its name implies, displays similar expression pattern to 
normal breast tissue. The significance of this subtype has yet to be determined, and some 
argue that it may represent a mere contamination of samples with normal breast tissue (Parvin 
et al., 2012; Huang et al., 2012; Parker et al., 2009).  
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Molecular classification of breast cancers (Malhotra et al., 2010). 
24 
 
1.3.3 Triple negative, basal-like and BRCA1-mutated breast cancers 
As mentioned before, the molecular subtypes of breast cancer display highly significant 
differences in prediction of overall survival with the basal like/triple-negative (ER-/PR-
/ErbB2-) subtype having the shortest survival.  Basal-like breast cancers (BLBCs) represent 
10%-25% of all breast tumors, depending on the demographics of the population. These 
tumors were so named because their neoplastic cells consistently express genes usually found 
in normal basal/myoepithelial cells of the breast including high molecular weight basal 
cytokeratins (CK; CK5⁄6, CK14 and CK17), vimentin and P-cadherin (Nielsen et al., 2004; 
van de Rijn et al., 2002; Gusterson et al., 2005; Lakhani  et al., 2001). BLBCs often affect 
younger patients, frequently lack expression of hormone receptors and HER2, show TP53 
gene mutations in up to 85% of cases, display exceedingly high level of proliferation related 
genes and express epidermal growth factor receptor (EGFR) in >60% of cases (Perou et al., 
2000; Sorlie et al., 2001; Hu et al., 2006). The high proliferative potential of BLBCs is 
largely associated with loss of function of RB1 and p53, critical regulators of cell cycle. Basal 
like cancers are also frequently harboring BRCA1 mutation. It is believed that this combined 
alteration of p53/RB and BRCA1 is also responsible for the high euploidy observed in these 
tumors, including a huge number of chromosomal changes and translocations (Perou, 2011). 
Despite the great interest in basal-like cancers, there is still no internationally accepted 
definition of these tumors. Actually, microarray based expression profiling analysis is the 
most used tool for the identification of basal-like breast cancers (Rakha et al., 2007). 
However, this technology is unlikely to be introduced among diagnostic tools for breast 
cancer patients, and results of microarray-based expression profiling using RNA extracted 
from formalin-fixed archival samples are not optimal (Penland et al., 2007). Therefore, 
several attempts to define an immunohistochemical surrogate for basal-like cancers have been 
described. The best example to date is the panel proposed by Nielsen and colleagues, where 
25 
 
basal-like cancers are defined as those lacking both ER and HER2 expression and expressing 
CK5/6 and EGFR. This panel has a specificity of 100% and a sensitivity of 76% for the 
identification of basal-like cancers (Nielsen et al., 2004). 
Triple-negative breast cancers (TNBCs) account for 10–17% of all breast carcinomas (Harris 
et al., 2006; Haffty et al., 2006; Dent et al., 2007) depending on the thresholds used to define 
ER and PR positivity and the methods for HER2 assessment. The majority of triple-negative 
cancers are high-grade invasive ductal carcinomas of no special type, metaplastic carcinomas 
and medullary cancers. The main characteristics of triple negative cancers that have emerged 
from the literature illustrate the similarities between basal-like and triple-negative tumors 
including the fact that they more frequently affect younger patients (<50 years) (Haffty et al., 
2006; Dent et al., 2007), are more prevalent in African-American women (Morris et al., 2007) 
and are significantly more aggressive than tumors pertaining to other molecular subgroups 
(Haffty et al., 2006; Dent et al., 2007). Although there is a great deal of overlap between 
triple-negative and basal-like breast cancers, this overlap is not complete. Most, but not all, 
BLBCs are TN and vice versa (Figure 1.6). Particularly, analysis of ER, PR and HER2 status 
of breast cancers classified by microarray-based expression profiling analysis, as pertaining to 
the basal-like subgroup, has revealed that 15-54% of them express at least one of these 
markers. On the other hand, only 56-84% of triple negative tumors express basal markers 
such as basal CKs and EGFR. Thus, triple-negative and basal-like breast cancers are not 
synonyms. However, patients with triple-negative breast cancer expressing a basal phenotype 
have a significantly shorter disease-free survival than those with triple-negative phenotype 
with a basal-like profile.  
Mutation of the BRCA1 gene confers a lifetime risk of up to 80% of developing breast cancer 
(Narod and Foulkes, 2004). BRCA1 is a multifunctional protein with roles in DNA damage 
repair, cell cycle control, transcriptional regulation and ubiquitination. It participates in 
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transcriptional regulation at several levels, interacting with sequence specific transcription 
factors, RNA polymerase II and enzymes involved in chromatin remodeling (Bochar et al., 
2000; Zhang et al., 1998; Wang et al., 1998). BRCA1 transcriptional targets also possess 
tumor suppressor functions with roles in stress responses, cell cycle checkpoints, apoptosis 
and DNA repair (Mullan et al., 2005). The diverse functions of BRCA1 and its ability to 
suppress tumors through multiple mechanisms are highlighted by the range of mutations in 
BRCA1 resulting in defects in specific and distinct functions of BRCA1, all of which result in 
the development of breast cancers. More recently, a role for BRCA1 in stem cell regulation 
and the control of mammary gland differentiation has been suggested (Foulkes, 2004). It has 
been proposed that a primitive stem or early progenitor cell may be the target cell for 
transformation and therefore represents the origin of BRCA1 related breast cancers (Liu et al., 
2008; Lim et al., 2009; Molyneux et al., 2010; Proia et al., 2011). 
There is increasingly evidence to suggest a link between the BRCA1 pathway and triple-
negative/basal-like breast cancers (Turner et al., 2004; Turner and Reis-Filho 2006; Figure 
1.6). In fact, the vast majority of tumors arising in BRCA1 germ-line mutation carriers, in 
particular those diagnosed before 50 years of age, have morphological features similar to 
those described in basal-like cancers and they display a triple negative and basal-like 
phenotype as defined by immunohistochemistry or expression arrays (Foulkes et al., 2004; 
Lakhani et al., 2005; Sorlie et al., 2003). In particular, BRCA1-mutated breast cancers closely 
resemble i) basal-like breast cancer subtypes, expressing normal basal cytokeratins ii) 
sporadic triple negative breast cancers, lacking estrogen receptor and progesterone receptor 
expression and expressing low levels of Her2. Although sporadic basal-like cancers and 
tumors arising in BRCA1 mutation carriers show similar molecular genetic profiles (Wessels 
et al., 2002), they differ in the lack of BRCA1 somatic mutations in sporadic basal-like 
cancers. Despite this lack of BRCA1 mutations, it has recently been demonstrated that the 
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BRCA1 pathway may be dysfunctional in sporadic basal-like tumors. Therefore, BRCA1 
function can be abrogated both by mutation and downregulation of expression (referred to as 
‘BRCAness’). It has been hypothesized that this down-regulation would be mediated by 
epigenetic mechanisms, such as gene promoter methylation and/or transcriptional silencing of 
BRCA1 (Turner et al., 2004; Turner and Reis-Filho, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Schematic representation of the overlap between triple negative (TNBC), 
basal-like (BLBC) and BRCA1-muated breast cancers (Carey et al. 2010).  
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1.4 The cell of origin of breast bancers   
1.4.1 Breast cancer stem cells  
Al Hajj and colleagues were the first to identify a subpopulation of human breast cancer stem 
cells which initiated tumors in immune-deficient NOD/SCID mice (Al Hajj et al., 2003). 
They used a set of cell surface markers to sort cells with an increased tumourogenic capacity. 
In particular, cells which were CD44
+
CD24
low
EpCAM
+
 and lineage- (cells lacking markers 
CD2, CD3, CD10, CD16, CD18, CD31,CD64 and CD140b), isolated from one primary breast 
cancer and eight metastases, were able to form heterogeneous tumors eight out of nine times. 
As few as 200 CD44
+
CD24
low
EpCAM
+
lin
-
 cells transplanted into NOD/SCID mice could 
form tumors with 100% efficiency, while CD44
-
CD24
+
EpCAM
- 
cells formed no tumors. 
CD24, also known as heat stable antigen (HAS), is an adhesion molecule specifically 
expressed in luminal epithelial cells in human mammary gland. Thus, the low expression of 
luminal-specific protein CD24 in cells able to form tumors suggests a basal cell origin of 
tumor stem cells. The tumors contained not only the CD44
+
CD24
low
EpCAM
+
lin
-
 tumor-
initiating cells but also the phenotypically diverse non-tumorigenic cells that comprise the 
bulk of tumors. A subsequent study by Ponti and colleagues carried out on 16 breast lesions 
(13 primary invasive carcinomas, one recurrent carcinoma and two fibroadenomas), using the 
sphere culture technique, resulted in the production of three long-term primary cultures which 
had self-renewing capacity and could differentiate into the different breast lineages (Ponti et 
al., 2005). Almost all sphere-derived cells were found to be CD44
+
CD24
low
, however, cells 
with self-renewal capacity only accounted for 10–20% of the total cell number, showing that 
only a sub-group within the CD44
+
CD24
low 
cells had self-renewal capacity. Thus, both the 
mammosphere culture system and the cell surface marker selection enriched for tumor 
initiating cells. However, the enriched rather than pure CSC population that these methods 
produce, and recent data suggesting that the regulation of CD24 is dynamic both in vitro and 
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in vivo (Meyer et al., 2009), have highlighted the need for additional markers to further 
discriminate the BCSC (see section 1.5c). 
 
1.4.2 Functional classification of breast cancers  
Comparison of the transcriptional signatures of the molecular breast cancer subtypes with 
gene expression profiles of cell subsets isolated from mammary tissue suggests that different 
molecular subtypes of breast cancer may arise from cells at various stages of differentiation 
along the mammary epithelial hierarchy. In other words, molecular subtypes of breast tumors 
may be reflective of arrest at different stages of epithelial cell development (Figure 1.7). In 
this scheme, the claudin-low group includes the most primitive tumors that are the most 
similar to the mammary stem cell, and the next step on the pathway is the luminal progenitor, 
that seems to be the cell of origin of basal-like molecular subtype of breast cancers. BRCA1 
mutation is linked to this luminal progenitor/basal-like phenotype, and thus, somehow, loss of 
BRCA1 function may block further differentiation and keep a cell in this step of development. 
The next step in development is the luminal progenitor/basal-like cell that seems to be the cell 
of origin of the HER-2–enriched molecular subtype consisting basically in a loss of basal 
characteristics and a gain of luminal characteristics. The most differentiated groups are the 
luminal A and luminal B tumors (Prat and Perou, 2009; Perou, 2011). This scheme is 
somewhat complicated by the possibility that tumor cells may drift from their original 
configuration, losing specific markers of the cell of origin and taking on others (epithelial 
plasticity). A prime example of this is EMT, in which transformed epithelial cells switch to a 
mesenchymal phenotype whose expression profile resembles that of stem cells  (Bertos et al., 
2011). 
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Figure 1.7. Functional classification of breast cancers (Perou, 2011).  
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1.4.3 Luminal progenitor as cell of origin of BRCA1-mutated breast cancers 
Initial pathological and histological studies of BRCA1 mutant tumors suggested that these 
cancers may arise from the transformation of a cell type restricted to the basal layer of the 
breast epithelium (Liu et al., 2008). Recently, a number of publications have argued for the 
luminal progenitors as the target cells of transformation for BRCA1 mutated breast cancers 
(Lim et al 2009; Prat et al., 2010; Molyneux et al., 2010; Proia et al., 2011). One explication 
of the discrepancies between these studies could be that BRCA1 controls differentiation of 
stem cells into its progeny at multiple different steps and, depending on the degree of loss of 
BRCA1 expression, the block could occur at different levels: complete loss of BRCA1 could 
result in a block at the stem/early progenitor stage, while partial loss may allow the cells to 
continue to differentiate up to the luminal progenitors (Ginestier et al., 2009; Buckley and 
Mullan, 2012; Figure 1.8b,c). However, none of the studies to date have proven conclusively 
that the cell of origin of BRCA1 mutated breast cancers is a luminal progenitor cell. For 
example, Lim et al. showed that breast tissue from BRCA1-mutation carriers had an increased 
number of luminal progenitors. However, observation of an increased or abnormal pool of 
cells does not mean that these cells are the initial target for transformation. In fact, it is 
important to emphasize the distinction between the cell of origin and the cancer stem cell. The 
cells of origin refer to the original cells that were transformed and therefore represent the 
cancer-initiating cells, while the cancer stem cells may be the result of their 
transformation/dedifferentiation ensuring tumor maintenance and propagation. Thus, 
expanded populations of aberrant progenitor cells observed in many recent studies, could 
represent either the cells of origin or cancer stem cells. Identification of the cells of origin and 
the cancer stem cells of BRCA1 related cancers will help in establishing diagnosis and in 
developing novel therapies in the future.  
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Figure 1.8. Schematic representation of potential outcomes of loss of BRCA1 
function on differentiation. (a) Normal mammary gland differentiation. (b) Model 
proposed by Lim et al. where heterozygous BRCA1 inactivation results in an increase in 
luminal progenitors with a block in differentiation down other lineages. (c) Model 
proposed by Liu et al. where complete loss of BRCA1 function results in a block in 
differentiation from the bipotent progenitor and therefore an increase in stem/early 
progenitor cells (Buckely and Mullan, 2012).  
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1.5 Resources, tools and models to study breast cancer stem cells  
1.5.1  Human breast cancer cell lines  
Human breast cell lines have long served as models for a wide array of applications including 
the study of molecular, cellular, and biochemical mechanisms that regulate breast epithelial 
biology. Their ability to accurately reflect phenotypes of tumors remains controversial. 
Several studies have suggested that cell lines exhibit genetic alterations due to adaptation of 
culture environment, and are poor predictors of in vivo sensitivity to drug efficacy (Perou et 
al., 2000; Sorlie et al., 2001). However, other studies have indicated that cell lines are 
appropriate models to study tumor because they mirror many of the biological and genomic 
properties found within primary human tumors (Bergamaschi et al., 2006; Chin et al., 2006). 
Genomic approaches have revealed that, like primary tumors, the gene expression signatures 
of breast cancer cell lines can distinguish luminal from basal subtypes of breast cancer. 
Moreover, cell line-derived gene signatures can correctly classify human tumor samples, 
suggesting that, despite their acquired ability to grow in vitro and acquired mutations 
following adaptation to culture conditions, cell lines continue to share many of the molecular 
and genetic features of the primary breast cancers from which they were derived (Keller et al., 
2010). Actually, breast cancer cell lines are widely used as models to study breast cancer stem 
cells. Recently, based on transcriptional profiling, breast cancer cell lines have been classified 
in one luminal and two basal-like (A and B) subtypes. Luminal lines resemble luminal A/B 
tumors, basal-A lines resemble basal-like tumors, and basal-B lines display many 
stem/progenitor cell characteristics (Kao et al., 2009).  I focused my thesis work on basal-A 
breast cancer cell lines, because they are related to basal-like tumors that are the tumor 
subtype targeted of my research. Particularly, I hypothesized that the basal-A BRCA1 mutated 
breast cancer cell line HCC1937 could be the best candidate for identifying novel cancer stem 
cell markers. To date, attempts to establish breast cancer cell lines from germ-line mutation 
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related breast cancers have been mostly unsuccessful. HCC1937 is a BRCA1 mutated cell line 
established from a primary non-metastatic IDC originating from a 24-year-old patient with a 
germ-line mutation. The cell line is homozygous for the BRCA1 5382insC mutation, whereas 
the patient’s lymphocyte DNA was heterozygous for the same mutation. HCC1937 also has 
an acquired mutation of TP53 with wild-allele loss, and an acquired homozygous deletion of 
the PTEN gene. No significant levels of progesterone or estrogen binding were observed in 
either the primary tumor or the HCC1937 cultured cells. Only very low levels of Her-2/neu 
were expressed (Tonk et al., 1998). Literature data concerning basal-like breast cancers 
induced by BRCA1 inactivation led me to hypothesize that these tumors, and likely the 
corresponding cell lines, might be appropriate to identify CSCs with a phenotype different 
from the classical CD44
+
/CD24
-/low  
phenotype. Infact, 
 
it has been reported that BRCA1 basal-
like breast cancers originate from luminal epithelial progenitors and not from basal stem cells 
(Lim et al., 2009; Molyneux et al., 2010).  Moreover, a recent study reported the existence in 
the HCC1937 cell line of a stem cell population that was not CD44
+
/CD24
-/low 
(Hwang-
Verslues et al., 2009). So, I used the HCC1937 cell line as model to identify novel BCSC 
markers in basal-like breast tumors. 
 
1.5.2 Mammosphere assay 
Cell culture in non-adherent conditions is a widely used tool to identify and isolate breast 
cancer stem cells. This technique was initially adapted to normal breast obtained from 
reduction mammoplasty. Human mammary stem and progenitor cells were able to survive in 
suspension and produce spherical colonies (mammospheres) which were enriched in early 
progenitor/stem cells and able to differentiate along the three mammary epithelial lineages 
and to clonally generate complex functional structures in reconstituted 3D culture systems as 
well as reconstitute human normal mammary gland in mice (Dontu et al., 2003). This system 
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is now widely used to study underlying mechanisms of growth under anchorage-independent 
conditions, and by extension, to discover pathways implicated in stem/progenitor cells 
survival. The mammosphere assay was also successfully used to establish long-term cultures 
enriched in stem/progenitor cells from invasive tumor samples. The mammospheres formed in 
these conditions were called tumorspheres. They showed an increase in CD44
+
CD24
-//low
 
cells, overexpressed neoangiogenic and cytoprotective factors, expressed the putative stem 
cell marker OCT4, and displayed high tumorigenic potential in NOD/SCID mice (Ponti et al., 
2005). Thus, the development of in vitro suspension culture systems not only provides an 
important new tool for the study of mammary cell biology, but also has important 
implications for understanding key molecular pathways in both normal and neoplastic stem 
cells. Mammospheres also showed an increase in “side population” (SP) fraction that is linked 
to a property of stem cells. Particularly, the progenitor/stem cell population have a resistance 
to environmental toxins, chemotherapeutic and radiation agents, often as a result of multidrug 
resistance (MDR) via expression of ABC (ATP-Binding Cassette) family of transporter 
proteins, a property not found in differentiated cells. One of the substrates of transporter 
proteins is the fluorescent Hoechst 33342 dye. So, stem/progenitor cells actively extruding 
Hoechst 33342 dye, become negative for this dye, whereas differentiated cells remain 
positive. The negative, stem-like population is called Side Population (SP).   
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1.5.3 Expression of surface markers 
Another widely used tool for the isolation of cancer stem cells is the expression of surface 
markers. The pioneering study by Clarke and colleagues used breast cancer xenografts to 
isolate a population of cells able to initiate tumors in NOD/SCID mice. This population 
displayed the surface marker phenotype CD44
+
CD24
- 
(Al-Haii et al., 2003).  Given the small 
number of tumors analyzed by Clarke’s group and the characteristics of these tumors (eight 
out of nine were pleural effusions), their findings cannot be applied to a larger number of 
tumors that cover the high diversity of breast cancer subtypes. In a subsequent study, Honeth 
and colleagues have resolved Al-Hajj’s study limitations by using a large collection of well 
characterized breast cancers in order to explore the prevalence of cells with different 
CD44/CD24 phenotypes within breast tumor subtypes (Honeth et al., 2008). Only 31% of the 
tumors analyzed contained CD44
+
CD24
-
 cells, ranging from 1% or less to 100% of the total 
tumor population, and the CD44
+
CD24
-
 phenotype was more common in basal-like tumors. 
The findings of Honeth and colleagues suggest that CD44
+
CD24
-
 is the phenotype associated 
with tumor initiating cells only in certain breast cancers. Furthermore, Hwang-Verslues and 
colleagues found the existence of a cancer stem cell population that was not CD44
+
CD24
-
 in 
the cell line HCC1937 (Hwang-Verslues et al. , 2009). According to this findings, Meyer and 
colleagues showed that both CD44
+
CD24
-
 and CD44
+
CD24
+
 cell populations sorted from ER 
negative breast tumors are tumorigenic in murine xenograft models, indicating that xenograft 
initiating cells are not always restricted to the CD44
+
CD24
+
 population (Meyer et al., 2010). 
Moreover, recent studies suggest that CD44
+
CD24
-
 antigenic phenotype is an hallmark of 
EMT rather than stem cells. Particularly, it has been demonstrated that induction of EMT 
results in the acquisition of stem properties and is associated with the surface expression of 
CD44
+
CD24
- 
antigenic profile (Mani et al., 2008; Morel et al., 2008) These and other studies 
have highlighted the need for additional markers to further discriminate the BCSCs. In the 
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present study, I explored as novel candidate BCSC markers a series of selected 28 surface 
antigens including molecules known to be stem cell and/or cancer stem cell markers and 
molecules involved in processes such as cell adhesion, migration, apoptosis, metastasis, cell 
signaling, proliferation and differentiation.  
 
1.5.4 Side Population and ABCG2 
One of the analyzed surface markers explored in the present study as novel BCSC markers, is 
the breast cancer resistance protein 1 (BCRP1). BCRP1 is a member of the ATP-binding 
cassette (ABC) transporter G family and it is also known as ABCG2 or CD338. It is a 655-
amino acid polypeptide and contains six putative transmembrane domains. The high BCRP1 
gene expression leads to increased drug efflux and reduced intracellular drug concentration 
resulting in decreased cytotoxicity. ABCG2 has been found overexpressed in several human 
tumors indicating its possible role in multidrug-resistant phenotype of various cancer cells. 
ABCG2 protein plays an important role in the stem cell research in fact, normal and cancer 
stem cells overexpress transmembrane transporters, including ABCG2/BCRP1. This protein 
excludes the fluorescent Hoechst 33342 dye from the cells and so, it seems to be one of the 
major mediators of side population. The strongest evidence linking ABCG2 and the side 
population phenotype comes from the nearly complete loss of the bone marrow in Abcg
_/_
 
mice (Zhou et al., 2002). Other supporting evidence is that side population cells preferentially 
express ABCG2 (Summer et al., 2003; Shimano et al., 2003) and that ABCG2 expression is 
detected in known stem/progenitor cells such as hematopoietic (Zhou et al., 2001) and neural 
stem cells (Cai et al., 2004). On the other hand, it should be noted that only a fraction of the 
side population cells expresses ABCG2 and that the two side populations and stem/progenitor 
cells express additional ABC transporters. Moreover, Patrawala et al. showed that, in contrast 
to the tumorigenic differences between the side population and non–side population cells, the 
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ABCG2
+
 and ABCG2
-
 cancer cells show very similar tumorigenic potentials  in vivo 
(Patrawala et al., 2005). 
The SP technique has been used for many years to isolate both normal and cancer stem cells 
from different organs and species (Hirschmann-Jax et al., 2004; Minn et al., 2007;  
Montanaro et al., 2004). SP cells isolated from mammoplasty of healthy patients, were found 
to express more BCRP1 than non-SP cells. Moreover, a specific BCRP1 inhibitor (Ko143) 
reduced SP formation, suggesting that BCRP1 confers the SP phenotype in mammary 
epithelial cells. Interestingly, SP cells did express neither luminal nor myoepithelial markers 
(MUC1/CD227 and CALLA/CD10) nor estrogen receptor (ER), whereas non-SP cells did 
(Clayton et al., 2004), suggesting that they are dedifferentiated. Cells isolated extract from 
healthy mammary gland, cultured in non-adherent serum-free culture conditions, and shown 
to be enriched in stem/progenitors cells, also display a dedifferentiated phenotype (Dontu et 
al., 2003). The SP fraction from uncultured mammary cells represented ~1% of cells. In 
contrast, in mammospheres, the SP fraction represented 27% of the cells and could generate 
bi-lineage colonies when cultured under differentiating conditions, suggesting that the SP 
fraction contained the bipotent progenitors and was capable of mammosphere formation 
(Dontu et al., 2003). 
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II. RATIONALE AND AIM OF THE THESIS 
 
Breast cancer is the first human carcinoma for which a putative cancer stem cell 
subpopulation (BCSCs, breast cancer stem cells) has been isolated with the CD44
+
/CD24
-
/low 
phenotype (Al-Hajj et al., 2003). Given the small number of tumors analyzed by Clarke and 
colleagues and the characteristics of these tumors (eight out of nine were pleural effusions), 
their findings cannot be enlarged to the tumors that cover the high diversity of breast cancer 
subtypes. In a subsequent study, Honeth and colleagues have resolved Clarke’s study 
limitations and demonstrated that CD44
+
CD24
-
 is the phenotype associated with tumor 
initiating cells only in certain breast cancers (Honeth et al., 2008). According to this findings, 
Meyer and colleagues showed that both CD44
+
CD24
-
 and CD44
+
CD24
+
 cell populations 
sorted from ER (estrogen receptor) negative breast tumors are tumorigenic in murine 
xenograft models, indicating that xenograft initiating cells are not always restricted to the 
CD44
+
CD24
+
 population (Meyer et al., 2010). 
Some questions arise from these studies: Is the CD44
+
CD24
-
 phenotype associated with tumor 
initiating cells only in certain breast cancers? Are cancers that do not contain cells with this 
phenotype driven by a different cancer stem cell? If this is the case, do these cancer stem cells 
not bearing the CD44
+
CD24
-
 phenotype have a different origin? At this point, many studies 
are still debating on the relevance of CD44 and CD24 in identifying BCSCs. Thus, there is the 
need for additional markers to further discriminate the BCSCs.  
The central aim of the present thesis is to identify novel markers  for  isolation and 
characterization of breast cancer stem cells. To achieve this aim, my work was conducted to 
reach three objectives:  
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1) Identification of putative BCSC markers other than CD44 and CD24 in breast cancer cell 
lines representative of different molecular breast cancer subtypes. 
To reach this objective, I conducted two different tasks: (1a) First, I characterized different 
breast cancer cell lines by flow cytometry, which allowed me evidencing novel putative 
markers; then, (1b) I isolated from the breast cancer cell lines the putative BCSC 
subpopulations expressing the markers identified in task 1a). 
2) Validation of stem properties and tumorigenicity of the newly identified putative BCSC 
subpopulations. 
(2a) I first conducted in vitro experiments to explore stem properties of isolated cell 
subpopulations; then, (2b) I conducted in vivo experiments in NOD/SCID and nude mice to 
explore the tumorigenicity of the putative BCSCs isolated. 
3) Standardization of flow-cytomertic methods to study primary cultures from human breast 
cancer tissues. 
Tasks #1 and #2 were accomplished in the first part of the present thesis, and they allowed 
identifying and isolating a subpopulation of cells with stem cell-like properties in a breast 
cancer cell line. Task #3 was accomplished in the second part of the present thesis, and it will 
subsequently be used to isolate the putative BCSC population identified in tasks #1 and #2 
from human breast cancer tissues. 
While accomplishing task #3, we have also determined whether cell cultures established from 
human breast cancer tissues maintain the cellular heterogeneity of primary tissues and may 
therefore be used for in vitro modeling of breast cancer subtypes. To this aim, we used a 
much larger vocabulary of surface markers than those used in previous studies to characterize 
primary cultures by flow cytometry and we analyzed luminal cytokeratins CK18, CK19, and 
myoepithelial/basal CK5, SMA (alpha-smooth muscle actin) and vimentin expression by 
western blot. 
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III. PART 1: 
Identification of a novel BCSC phenotype in the basal-A BRCA1 mutated breast 
cancer cell line HCC1937 
 
In the first part of the thesis task #1 and task #2 of the central aim have been accomplished. 
1) Identification of putative BCSC markers other than CD44 and CD24 on breast cancer cell 
lines representative of different molecular breast cancer subtypes.  
To reach this objective, first, different breast cancer cell lines have been characterized by flow 
cytometry, allowing to evidence new putative markers in breast cancer cell line HCC1937. 
Then, the putative BCSC subpopulations expressing the markers of interest have been isolated 
by cell sorting. 
2) Validation of stem and tumorigenic properties of the newly identified putative BCSC 
subpopulations by in vitro and in vivo assays. 
This work allowed to identify a novel BCSC phenotype, CD44
+
CD24
+
CD338
bright
,  in the 
basal-A BRCA1 mutated breast cancer cell line HCC1937. 
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3.1  RESULTS 
 
3.1.1 Surface expression profile of breast cancer cell lines. 
3.1.1.1  Experimental strategy: cell lines and surface markers studied 
In order to identify novel BCSC markers, I started with a wide flow cytometry 
characterization of several cell lines representative of the different molecular subtypes of 
breast cancer. I focused my interest on the luminal MCF7, the basal-B Hs578T, and two 
basal-A cell lines, BT-20 and HCC1937. Table 1 shows the main characteristics of the chosen 
cell lines. I evaluated the expression of thirty surface antigens that are involved in processes 
such as cell adhesion, migration, apoptosis, metastasis, cell signalling, proliferation and  
differentiation, and molecules known to be stem cell and/or cancer stem cell markers in other 
tumors (Table 2). Figure 3.1 shows the result of surface markers analysis in HCC1937 cell 
line. I performed flow cytometry (FCM) analysis using a four-color flow FCM panel. In fact, 
I stained cells with monoclonal antibodies against the two classical breast cancer stem cell 
markers, CD44 and CD24, combined with pairs of antibodies against molecules explored as 
potential novel BCSC markers (Table 5,  Materials and Methods section). Hence, I could 
analyze and compare the expression of 28 surface markers in the CD44
+
/CD24
-/low 
and 
CD44
+
/CD24
+ 
cell subpopulations of each cell line. 
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Table  1. Breast cancer cell lines characterized by flow cytometry. 
 
Cell Line Source Disease Receptors Oncogenes 
Cell Line 
subtype 
Tumor 
subtype 
BT-20 P.Br IDC TPN 
 
Basal-A Basal-like 
HCC1937 P.Br DC TPN BRCA1 Basal-A Basal-like 
Hs 578 T P.Br IDC TPN 
 
Basal-B ? 
MCF-7 PE IDC 
ER+ PR+ 
HER2-  
Luminal Luminal 
 
 
DC = Ductal Carcinoma; IDC = Invasive Ductal Carcinoma; ER = Estrogen Receptor; PR = 
Progesterone Receptor; HER2 = Human Epidermal growth factor Receptor 2; TPN = Triple 
Negative; P.Br = Primary Breast; PE = Pleural Effusion. 
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Table  2.  Molecular identity and function of the antigens analyzed in breast cancer cell lines. 
 
CD Molecule Function References 
CD9 P24 Cell adhesion and migration Nishida 2009 
CD10 CALLA Antigen overexpressed on many tumors Iwaya 2002 
CD24 HSA Adhesion and  metastatic tumors Al-Hajj 2003 
CD26 DPPIV Exopeptidase, tissue restructuring Pro 2004 
CD29 β1 integrin Adhesion to matrix proteins Charafe-Jauffret 2009 
CD44 H-CAM Cell polarity, suppression of apoptosis, 
metastasis 
Al-Hajj 2003 
CD47 Rh-associated protein Cell activation, apoptosis, cell spreading Manna 2004 
CD49b α2 integrin Cell adhesion to collagen and laminin Langsenlehner 2006 
CD49f α6 integrin Cell adhesion, migration, cell surface 
signaling 
Cariati 2008 
CD54 ICAM Cell adhesion, immune reactions Rosette 2005 
CD55 DAF Protection against complement Ikeda 2008 
CD59 MIRL Protection from complement-mediated lysis Babiker 2005 
CD61 β3 integrin Cell adhesion, cell signaling Charafe-Jauffret 2009 
CD66b CEACAM8 Cell adhesion, cell signalling Lasa 2008 
CD66c CEACAM6 Cell adhesion, cell signalling Lasa 2008 
CD81 TAPA-1 Response to antigens Yáñez-Mó 2009 
CD90 Thy-1 Cell adhesio and differentiation Yamazaki 2009 
CD105 ENG (Endoglin) Angiogenesis, vessel wall integrity Henry 2011 
CD133 Prominin 1 Unknown Wright 2008 
CD151 PETA-3 Cell adhesion Sadej 2009 
CD164 MGC-24 Adhesion and homing Havens 2006 
CD165 AD2 Unknown Seon 1984 
CD166 ALCAM Adhesion, organ development Kulasingam 2009 
CD184 CXCR4 Increased expression in mammospheres Krohn 2009 
CD200 OX2 Immunosuppression Kawasaki 2007 
CD227 MUC1 Response to hormones and cytokines Stingl 2009 
CD324 E-Cadherin Cell adhesion, tumor suppression Prasad 2009 
CD326 EpCAM Cell adhesion Stingl 2009 
CD338 ABCG2 Pumping cytotoxic drugs out of cells Zhou 2001 
CD340 Her2/neu Cell growth and differentiation Paik 2008 
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3.1.1.2 Surface expression profile of HCC1937 basal-A cell line. 
To evaluate the differences of surface markers expression between CD44
+
/CD24
-/low 
and 
CD44
+
/CD24
+ 
subpopulations of each cell line, I determined the ratio between the mean 
fluorescence intensity (MFI, see section 6.2 of the Flow Cytometry Appendix) of each CD in 
CD44
+
/CD24
+
 and CD44
+
/CD24
-/low 
cells. This analysis didn’t show any significant 
differences of surface markers expression between CD44
+
/CD24
-/low 
and CD44
+
/CD24
+ 
subpopulations of MCF7, Hs578T and BT-20 cell lines. Contrarily, there were some 
interesting differences in the HCC1937 basal-A cell line. Table 3 shows the ratio of MFI of 
each antigen evaluated in the two cell subpopulations, CD24
+
 and CD24
-
, present in the 
HCC1937 cell line. Most CDs displayed a ratio near to 1 which indicated an equal or very 
similar expression in the two cell subpopulations, whereas CD338/ABCG2 and 
CD10/CALLA displayed a ratio greater than two (2.4) which indicated that they are expressed 
at a higher level in the CD24
+
 than in CD24
-
 cell subpopulation. This observation suggested 
that, in the HCC1937 basal-like breast cancer cell line, some stem cell markers are highly 
expressed in the CD44
+
/CD24
+
 subpopulation. Particularly, CD338, that has been reported to 
be highly expressed in stem cells (Zhou et al., 2001; Cai et al., 2004), displays a complex 
expression in the HCC1937 cell line (Figure 3.2). Indeed, some HCC1937 cells expressed 
CD338 at low level, whereas others expressed it at high level. Strikingly, the MFI of CD24 in 
cells overexpressing CD338 was 4.7 fold higher than in cells expressing CD338 at low level 
(5,200 and 1,100 respectively; p<0.05). This result indicates that CD338 overexpressing cells 
also do overexpress CD24. I thus reasoned that HCC1937 cell line could contain a putative  
CD24
+
CD338
+  
CSC subpopulation. 
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Table 3. Analysis of surface antigens expression in CD24
hi
 and CD24
-/low
 cell subpopulations 
              of HCC1937 cell line.  
 
Antigen (CD) MFI in  CD24
hi 
cells MFI in CD24
hi 
cells RMFI p-value 
49f 35,075.33 26,455.33 1.3 0.1065 
338 3,053 1,291.75 2.4 0.0009 
90 5,369.33 3,379.33 1.6 0.0609 
133 1,654 1,358.67 1.2 0.4104 
47 10,610 8,321.33 1.3 0.3071 
200 1,541.67 1,121.33 1.4 0.1801 
227 7,171.33 4,982.33 1.4 0.1003 
10 1,877 764,5 2.4 0.0129 
324 7,075.33 4,192.33 1.7 0.1451 
29 78,047,33 63,620 1.2 0.0522 
66c 13,176 8,175.33 1.6 0.1536 
61 1,266.67 1,195.33 1.0 0.4328 
164 5,068.33 3,419 1.5 0.0323 
340 4,105 2,653.67 1.5 0.1489 
49b 98,598.33 70,022.33 1.4 0.0505 
184 2,042 1,100 1.8 0.2849 
9 34,267 20,817.33 1.6 0.1232 
54 35,329 22,530.4 1.6 0.0970 
26 3,305.67 2,486 1.3 0.0134 
55 57,866.33 54,469 1.1 0.7307 
81 2,4084.2 22,350.2 1.1 0.0084 
151 5,578 3,677 1.5 0.0117 
66b 2,012 1,566.33 1.3 0.0585 
59 5,868 3,682.33 1.6 0.0246 
165 2,406 1,686 1.4 0.0339 
166 4,753.5 3,255 1.5 0.3157 
326 40,513.67 33,192 1.2 0.0640 
105 2,859 2,228.33 1.3 0.0630 
 
MFI = Mean Fluorescence Intensity. RMFI = MFI in CD24
hi
/MFI in CD24
-/low
. Each measure 
was carried out 3-5 times. Most CDs display a RMFI near to 1 indicating an equal or very 
similar expression in the two cell subpopulations, whereas CD338 and CD10 display a ratio 
greater than two indicating that they are higher expressed in the CD24
+
 than CD24
-/low
 cell 
subpopulation (p = 0.0009 and 0.0129, respectively). 
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Figure 3.1. Flow cytometry analysis of surface markers expression in the HCC1937 cell 
line. HCC1937 cell line was prepared for flow cytometry analysis as described in Materials and 
Methods. For each tube 10,000 events were recorded and analyzed.  (a,b,c): gating strategy used 
to remove debris, cell clusters and dead cells. (a) In order to exclude dead cells and debris, cells 
were gated on a two physical parameters dot plot measuring forward scatter (FSC) vs side 
scatter (SSC) (see section 6.2 of Flow Cytometry Appendix); (b) then doublets were excluded 
by gating cells on FSC-Height vs FSC-Area dot plots (see section 6.2 of Flow Cytometry 
Appendix); (c) finally, in order to further exclude dead cells, I gated Sytox Blue negative cells. 
This gating strategy was used to define the cell population subsequently analyzed for the 
expression of surface markers.  (d) Surface markers expression on cells gated as described. The 
expression of each antigen is represented on a frequency distribution histogram (count vs FITC 
or PE signal, see section 6.2 of Flow Cytometry Appendix). The vertical marker on each 
histogram used to detect the antibody-positive cells was established using the appropriate 
negative controls. 
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MFI of  
CD24 in  
CD338
+
  
cells 
 ~ 5200 
MFI of  
CD24 in  
CD338
-
  
cells 
 ~ 1100 
Figure 3.2. Expression of CD338/ABCG2 in the HCC1937 cell line.  CD338
+
 cells (panel a, 
red events) as compared to CD338
-
 cells (panel a, blue events) displayed a mean fluorescence 
intensity (MFI) of CD24 4.7 fold higher (p<0.05), as shown by monoparametric histogram of 
CD24 expression (panel b) and by CD338 vs CD24 dot plot (panel c). 
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3.1.2. Cell sorting of different cell subpopulations from HCC1937 basal-A cell line 
Flow cytometry analysis led me to hypothesize that HCC1937 cells include a subpopulation 
of stem/progenitor cells overexpressing CD338 and CD24. To validate this hypothesis, I 
isolated with the cell sorting technique (see section 6.3 of Flow Cytometry Appendix) 
subpopulations of the HCC1937 cell line expressing or not the markers of interest, CD24 
and/or CD338, and compared their stem cell-like and tumorigenic properties through various 
assays. 
 
3.1.2.1 Isolation of CD338 positive and negative cells and improvement of cell sorting 
purity 
The development of a monoclonal antibody, named 5D3, specifically reacting with the human 
ABCG2 protein on the cell surface, has previously been reported to successfully sort out 
viable ABCG2-expressing cells (Zhou et al., 2001). 5D3 was thus used as a tool to sort 
CD388 positive and negative populations out of HCC1937 cells. 5D3 binding to its 
extracellular epitope strongly depends on the conformation of ABCG2 (Ozvegy-Laczka et al., 
2005), making the binding particularly unstable. For this reason, in the first part of the study 
the purity of sorted subsets was not as good as expected (Figure 3.4).  
Due to this technical limit, I tried to stabilize the binding of anti-CD338 antibody in order to 
obtain an improvement of cell sorting purity. To this aim I used, during the cell sorting 
procedure, a cross-linker protein (PMPI, p-Maleimidophenyl isocyanate) known to be able to 
increase the 5D3 binding to ABCG2. The PMPI cross-linker protein is able to fix the epitope 
on a monomeric ABCG2 protein, without disrupting its activity. Figure 3.3 shows the 
structure of ABCG2, the external epitope recognized by 5D3 and the stabilizing activity of 
cross-linker proteins. The use of  PMPI led to an improvement of sorting purity which 
increased from 50% to 90%. 
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Figure 3.3. ABCG2 structure and cross-linker protein activity. Because ABCG2 is a half-
transporter, bearing only one of each of the characteristic ABC family domains (the ATP-
binding domain and transmembrane domain), it has to form a homodimer to become 
functionally active. The ABCG2 homodimer is covalently linked via a disulfide bond formed 
by cysteines at position 603, localized in the large 55-amino acid-long third extracellular loop 
(ECL3) of the protein. In ECL3, ABCG2 has two other cysteines at positions 592 and 608. 
These two residues are indicated as forming an intramolecular disulfide bridge that influences 
plasma membrane targeting and substrate specificity of the transporter. It seems that activity 
of cross-linker proteins at the level of cysteines 592 and 608, is responsible for 5D3 
increasing binding (Desuzinges-Mandon et al., 2010). 
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Figure 3.4. Purity of CD338 positive and negative sorted subsets. 5D3 antibody binding to 
its epitope strongly depends by ABCG2 conformation, so it is not stable. For this reason, in 
the first part of the study the purity of CD338 positive sorted subsets was low (50%, lower left 
panel), with a contamination by negative cells in CD338 positive sorted subset. The use of the 
PMPI cross-linker protein during the cell sorting procedure, increased 5D3 antibody binding 
leading to an improvement of cell sorting purity (95%, lower right panel). 
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3.1.2.2 Highlight on CD338 expression in HCC1937 cell line and cell sorting of three 
different CD338 cell subpopulations 
In the initial phase of the study, expression analysis and cell sorting experiments were 
performed using a BD FACSAria I Cytometer (see Materials & Methods and Flow Cytometry 
Appendix). This cytometer use the blue laser to discriminate the different fluorescence 
intensities of PE (Phycoerythrin) that is the fluorochrome conjugated to the 5D3 antibody 
used in the present study. This laser is able to discriminate just CD338 positive and CD338 
negative subsets (+ and – respectively in Figure 3.5, upper left panel). These two subsets were 
sorted out from HCC1937 cell line in the initial phases of the study. I next had the opportunity 
to analyze the expression of CD338 with a BD LSR II four-laser flow cytometer. This 
cytometer is equipped also with another laser, the yellow-green laser, that discriminates the 
different PE fluorescence intensities more accurately than the blue laser (see section 6.4 of 
Flow Cytometry Appendix). Taking benefit of this cytometer, a third cell subpopulation 
expressing an intermediate level of CD338 could be highlighted. HCC1937 cells are thus 
constituted of three populations 1) CD338
+/bright
 expressing CD338 at high level and 
consisting just in 1% of the total cell line; 2) CD338
neg
 not expressing CD338 and 
representing about 20% of the total cell line; 3) CD338
+/low 
expressing CD338 at an 
intermediate level and consisting in about 79% of the total cell line (red, yellow and blue 
events, respectively in Figure 3.5, upper right panel). As the LSR II Cytometer is 
unfortunately an analyzer, but not a cell sorter, cell sorting had to be performed with the 
FACSAria cell sorter. Nonetheless, I attempted to sort the three populations on the base of the 
comparison between the two images given by blue and yellow-green lasers of LSR II. As 
showed in figure 3.5, there was a strong overlap between CD338 negative and low cells 
analyzed with the blue laser (upper left panel). Consequently, the purity of these two sorted 
subpopulations was not fully reliable. Figure 3.5 shows an example of cell sorting of bright, 
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low and negative cell subsets performed with the FACSAria I cell sorter. To better define the 
level of contamination between the three different populations after cell sorting, I looked at 
ABCG2 expression performing a RT-qPCR with sorted cells, using as control the unsorted 
total cell line. As shown in figure 3.6, CD338
bright
 sorted cells displayed the highest level of 
ABCG2 mRNA (2.09), whereas CD338 negative sorted cells displayed the lowest one (0.33). 
CD338
low
 sorted cells displayed an expression level that was intermediate between CD338 
negative sorted cells and the unsorted total cell line (0.58). These results indicate that CD338 
cell sorting, based on the different ABCG2 surface protein expression, led to the separation of 
the three subpopulations with different ABCG2 gene expression levels, i.e. three different cell 
types. However, the mRNA level difference between CD338
low
 and CD338
neg
 sorted 
subpopulations is very low, thus confirming a contamination by CD338
low
 cells in CD338
neg
 
sorted subpopulation. 
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Figure 3.5. Expression of CD338 in HCC1937 cell line and cell sorting of three cell 
subsets.  Upper panels: FACSAria I Cytometer is equipped with the blue laser that is able to 
discriminate just CD338 positive (upper left panel, red events) and CD338 negative (upper 
left panel, blue and yellow events). LSR II Cytometer is equipperd also with the yellow-green 
laser that is able to discriminate three different cell subsets: bright, low and negative cells 
(upper right panel). Blue events, that seemed to be CD338 negative cells according to the blue 
laser, actually are CD338 positive (as shown by the yellow laser), although expressing CD338 
at lower level than CD338
bright
 cells. Lower panels: example of sorting of the three subsets 
performed with FACAria I sorter on the base of the images given by the two lasers of  LSR II 
analyzer.  
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Figure 3.6. ABCG2 expression analysis in sorted cell subpopulations. Relative mRNA 
expression levels of ABCG2 in CD338
bright
, CD338
low
 and CD338
neg
 sorted populations as 
estimated by qPCR. The level of mRNA expression in the parental cell line (Unsorted) was 
set = 1.0 for reference purposes. HPRT1 was used as a reference gene. 
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3.1.3 Mammosphere assay with unsorted HCC1937 cell line 
Mammosphere forming assay, consists in the evaluation of the ability of cells to grow in non-
adherent conditions and to establish structures named as mammospheres, a property 
considered as a hallmark of mammary stem/progenitor cells. I first performed mammosphere 
formation assay with unsorted cells and next examined the antigenic expression of cells that 
constitute the established mammopheres (Figure 3.7). Third-generation mammospheres were 
disaggregated to a single cell suspension that was subsequently analyzed by flow cytometry. 
The percentage of CD338
bright
 cells in mammospheres was 4.9 fold higher than that in 
adherent cell line (mean ± SEM: 8.300% ± 0.5508 and 1.750% ± 0.0866 respectively, 
p<0.0001). Furthermore, the MFI of CD338 in mammosphere-derived cells was 3.8 fold 
higher than that in adherent cell line. This observation strongly supports the assumption that 
CD338 positive cells display some stem cell-like properties. It’s also interesting to note that 
all cells from the adherent HCC1937 cell line express CD326/EpCAM and CD49f/α6-integrin 
(Figure 3.7, panel c), whereas most cells from mammospheres lose the expression of these 
two markers (Figure 3.7, panel f, gray events). Particularly, in HCC1937-derived 
mammospheres just CD338
bright
 cells continue to express CD326/EpCAM and CD49f/α6-
integrin (Figure 3.7, panel f, red events). CD326 and CD49f delineate distinct subpopulations 
in human mammary tissue and it has been demonstrated that the double positive subset 
consists of luminal progenitors (Lim et al. 2009). The fact that, in HCC1937-derived 
mammospheres, just CD338 positive cells continue to express CD326/EpCAM and 
CD49f/α6-integrin could suggest a progenitor nature for these cells. 
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Figure 3.7. Flow cytometry characterization of mammospheres originate from unsorted 
HCC1937 cell line. (a, b, c): expression of CD338, CD326 and CD49f in cells grown in 
adherent conditions. (d, e, f): expression of CD338, CD326 and CD49f in cells obtained from 
the disaggregation of mammospheres. Mammospheres were generated from the HCC1937 
cell line as described in Materials & Methods. Third-generation mammospheres were 
disaggregated to a single cell suspension that was subsequently analyzed by flow cytometry. 
The percentage of CD338
+ 
cells in mammospheres (e) is 4.9 fold higher (mean ± SEM: 
8.300% ± 0.5508 and 1.750% ± 0.0866 respectively, p<0.0001) than that in adherent cell line 
(b). The MFI of CD338 in mammospheres-derived cells is 3.8 fold higher than that in 
adherent cell line.  All cells from adherent cell line express CD326 and CD49f  (c) whereas 
most cells from mammospheres, except CD338
+
,  lose these two markres (f). 
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3.1.4 Filiation between the different CD338 sorted cell subpopulations 
To evaluate whether CD388
bright 
cells give rise to CD388 low cells, cells were sorted out and 
their antigenic phenotype was examined after culturing them for several weeks. Particularly, I 
separately cultured sorted CD338
bright
 and CD338
low 
 populations and I analyzed the 
expression of CD338 after four weeks. While the antigenic phenotype of CD388 low cells 
remains stable and homogeneous, CD388
bright
 cells gave rise to bright and low cells (Figure 
3.8). These results suggested a filiation from CD338
bright 
to CD338
low 
cells. The weak purity of 
CD388 negatively sorted out cell population avoided us performing similar experiments with 
this subpopulation. From this result, we can conclude that in the HCC1937 cell line CD338
low 
population could constitute the progeny of the most immature CD338
bright
 population. 
. 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Expression of ABCG2 in CD338
bright
 and CD338
low 
sorted cell 
subpopulations. CD338
bright
 and CD338
low 
cells were sorted out from HCC1937 cell line and 
plated in adherent conditions. After 4 weeks the two subcultures were detached and the 
expression of CD338 was analyzed by flow cytpmetry. 
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3.1.5 Side population in HCC1937 cell line 
Progenitor/stem cells are able to actively extrude the fluorescent Hoechst 33342 dye. They are 
consequently not stained with that dye, while differentiated cells are. The negative-Hoechst 
33342 cell population is named Side Population (SP) and ABCG2 seems to be one of the 
major mediators of side population. To study the side population in the HCC1937 cell line, I 
used the method described by Goodell et al. (see Materials and Methods). Strikingly, 
HCC1937 cell line includes  “side population” representing 1.4% of the total cell line, a 
percentage very similar to that of CD338
bright 
cells (Figure 3.9, left panel). Furthermore, 
treatment of HCC1937 with an inhibitor of ABCG2 (Reserpine) reduces the side population 
from 1.4% to 0.2%, supporting the concept that ABCG2 contributes to the dye exclusion in 
this cell population. This result indicated that, in the HCC1937 cell line there is an overlap 
between side population and CD338
bright 
cells, supporting the hypothesis that CD338
bright 
cells 
are stem/progenitor cells. 
 
 
 
 
 
 
 
 
Figure 3.9. Side Population in HCC1937 cell line. The method described by Goodell et al., 
was used to study side population in HCC1937 cell line. In cells treated with the ABCG2 
inhibitor Reserpine the percentage of “side population” decreased from 1.4% (left panel) to 
0.2% (right panel). 
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3.1.6 Mammosphere assays with cell subsets sorted out of HCC1937 cell line 
To  strengthen the hypothesis that stemness properties are specifically allotted to the CD24
hi
 
and/or CD338
bright 
cells
 
in HCC1937 cell line, the corresponding populations were sorted out 
and their mammosphere formation capability was compared to CD24 or CD338 negative 
couterparts. 
 
3.1.6.1 Mammosphere-forming efficiency of CD24
hi
 and 
 
CD24
-
 sorted cells  
To compare stem properties of CD24
hi
 and CD24
-
 cells, I performed three independent 
mammosphere assay experiments from sorted cell subpopulations. In particular, cells from 
HCC1937 cell line in adherent conditions were stained with anti-CD24 mAb and analyzed by 
flow cytometry. CD24
-
 and CD24
hi
 cells were separated through cell sorting and then plated 
in non-adherent conditions at a low density to generate mammospheres (Figure 3.10). The 
mammosphere formation assay (MFE) of CD24
hi
 cells was higher than that of CD24
-
 cells 
(mean ± SEM: 5.750 ± 1.031 and 0.500 ± 0.2877 respectively; p<0.0087). This result 
supports the assumption that stem cell-like properties are specifically allotted to the CD24 
positive cell subpopulation. 
 
3.1.6.2  Flow cytometry characterization of mammospheres from CD24
hi
 sorted cells 
Cells in human mammary tissue can be divided in three distinct subpopulations based on the 
expression of two surface markers, CD326 (EpCAM) and CD49f (α6-integrin). The 
CD49f
hi
/CD326
+
  subset consists of luminal progenitors (Lim et al., 2009; Keller et al., 2010). 
Mammospheres from CD24
hi
 sorted cells were disaggregated to single cell suspensions that 
were then labeled with antibodies against CD338, CD326 and CD49f.  The percentage of 
CD338
+  
cells in mammospheres generated from CD24
hi
 cells is 4.2 fold higher than that in 
mammospheres generated from CD24
- 
cells (mean ± SEM: 9.667% ± 2.002 and 2.300% 
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±1.050, respectively; p<0.05). Furthermore, the MFI of CD338 in CD24
hi  
mammospheres-
derived cells is 2.9 fold higher than that in CD24
-  
mammospheres-derived cells (Figure 3.10). 
Most cells from CD24
hi
 mammospheres  were found to be  CD326 and CD49f negative, with 
the exception of the  CD338
bright
 cells that were positive for both surface markers. This 
phenotype, namely double positivity for CD326 and CD49f, is a marker of “luminal 
progenitors”. I thus concluded that the CD338+ cell subpopulation likely displays luminal 
progenitors phenotype.  
 
 
Figure 3.10. Flow cytometry characterization of mammospheres from CD24
hi
 sorted 
cells. Cells from cell line in adherent conditions (a) were stained with anti-CD24 mAb and  
analyzed by flow cytometry (b). CD24
-
 and CD24
hi
 cells were separeted through cell sorting 
and plated in non-adherent conditions at a low density to generate mammospheres (c, d). 
CD24
hi
 cells were able to form mammosphere with a higher efficiency than CD24
-
 cells 
(mean ± SEM: 5.750 ± 1.031 and 0.500 ± 0.2877 respectively; p<0.0087).  Mammospheres 
generated from CD24
hi
 and CD24
-
 cells were disaggregated to  single cell suspensions that 
were then stained with anti-CD338 (e, f), anti-CD326 and anti CD49f  (g, h) MoAbs. The 
percentage of CD338
+  
cells in mammospheres generated from CD24
hi
 cells is 4.2 fold higher  
than that in mammospheres generated from CD24
-
 cells (mean ± SEM: 9.667% ± 2.002 and 
2.300% ±1.050, respectively; p<0.05) (e, f). The MFI of CD338 in CD24
hi  
mammospheres-
derived cells is 2.9 fold higher than that in CD24
- 
mammospheres-derived cells. Most cells 
from CD24
hi
 mammospheres, but not CD338
+
,  lose expression of CD326 and CD49f. 
a 
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3.1.6.3 Mammosphere-forming efficiency of CD24
hi
/CD338
bright
 and CD24
hi
/CD338
-
 sorted 
cells  
Next, I performed a two color cell sorting, that means I stained cells with monoclonal 
antibodies against both CD24 and CD338 and then separated CD24 positive population in 
CD338 positive and CD338 negative. Among the CD24 positive cells, those overexpressing 
the stem cell marker CD338 were able to form mammospheres with higher efficiency than 
CD338 negative cells (Figure 3.11; mean ± SEM: 13.0 ± 1.080 and 1.5 ± 1.190 respectively; 
p<0.05). This information corroborates the hypothesis that CD24
+
CD338
+
 cells display stem 
cell-like properties. 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Mammosphere-forming efficiency of CD24
hi
/CD338
bright
 and CD24
hi
/CD338
-
  
sorted cells. Cells from cell line in adherent conditions were stained with anti-CD24 and 
CD338 MoAbs and analyzed by flow cytometry (a). CD24
hi
/CD338
bright
 and CD24
hi
/CD338
-
 
cells were separeted through cell sorting and plated in non-adherent conditions at a low 
density to generate mammospheres (b, c). Among the CD24 positive cells, those 
overexpressing the stem cell marker CD338 were able to form mammospheres with higher 
efficiency than CD338 negative cells (mean ± SEM: 13.0 ± 1.080 and 1.5 ± 1.190 
respectively; p=0.0004). 
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1.3.6.4 Mammosphere-forming efficiency of CD338
bright
, CD338
low 
and CD338
neg
 sorted 
cells The use of the LSR II cytometer to analyze CD338 expression, led to the distinction of 
three different cell subpopulations 1) CD338
+/bright
 expressing CD338 at high level and 
consisting just in 1% of the total cell line; 2) CD338
neg
  not expressing CD338 and 
representing about 20% of the total cell line; 3) CD338
+/low 
expressing CD338 at an 
intermediate level and consisting in about 79% of the total cell line (see section 3.1.2.2 and 
Figure 3.5).  I thus sorted these three cell subsets and performed a mammosphere formation 
assay. For the first generation mammospheres, I plated sorted cells at 1,000 cells/well and I 
counted the number of spheres in each well after 3 weeks. As shown in figure 3.12, unsorted 
cells formed 4.2 spheres/well ± 2 (SD). CD338
bright
 and CD338
low 
formed a higher number of 
spheres than unsorted cells (7.5 ± 1.8 and 6.6 ± 2.5, respectively), whereas CD338
neg 
formed a 
lower number (3.8 ± 1.6). So CD338
bright
 cells displayed the highest MFE, whereas CD338
neg
 
displayed the lowest one. At the first generation, MFE of CD338
bright
 cells was 2 fold higher 
than that of CD338
neg 
. First generation mammospheres were dissociated to obtain a single 
cell suspension that was used to perform the second generation mammosphere assay by 
plating cells at a density lower than in first generation (100 cells/well instead of 1000 
cells/well). At the second generation the MFE difference between  CD338
bright 
 and CD338
neg  
was even more pronounced (Figure 3.12). Indeed, I counted 1.5 spheres/well from CD338
bright 
and 0.5 spheres/well from CD338
neg
. Finally, at the third generation assay, CD338
neg
 sorted 
cells were not able to form spheres (Figure 3.12). It’s very interesting to note that, between 
the different sorted subsets, there was a difference not only in the number of spheres, but also 
in their size. At the first and the second generation, mammospheres originated by CD338
bright
 
and CD338
low
 sorted cells were bigger than those originated by CD338
neg 
 sorted cells (Figure 
3.13). 
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Figure 3.12. Mammosphere-forming efficiency of CD338
bright
, CD338
low
 and CD338
neg
  
sorted cells. Cells from cell line in adherent conditions were stained with anti-CD338 mAb 
and  analyzed by flow cytometry. CD338
bright
, CD338
low
 and CD338
neg
 cells were separated 
through cell sorting and plated in non-adherent conditions at a low density to generate 
mammospheres. The upper panels (I) show the result of the first generation mammospheres: 
MFE ± SD: 4.2 ± 2 (unsorted cells), 7.5 ± 1.4 (CD338
bright
), 6.6 ± 2.5 (CD338
low
) and 3.8 ± 
1.6 (CD338
neg
). The central panels (II) show the result of the second generation 
mammospheres: MFE ± SD: 1.1 ± 0.9 (unsorted cells), 1.5 ± 1.3 (CD338
bright
), 0.9 ± 0.9 
(CD338
low
) and 0.5 ± 0.9 (CD338
neg
). The lower panels (III) show the result of the third 
generation mammospheres: unsorted cells: 3 spheres/44wells, CD338
bright
: 8 spheres/44wells, 
CD338
low
: 5 spheres/44wells,  CD338
neg
: any spheres.  
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Figure 3.13. Size of mammospheres originated by CD338
bright
 CD338
low 
and CD338
neg
 
sorted cells. At the first and second generation, mammospheres originated by CD338
bright
 and 
CD338
low
 sorted cells were bigger than those originated by CD338
neg 
sorted cells.  First 
generation mammospheres: size (μm) ± SD: 145.8 ± 15.28 (unsorted cells), 169.9 ± 14.66 
(CD338
bright
), 197.9 ± 27.28 (CD338
low
) and 112.5 ± 18.75 (CD338
neg
). Second generation 
mammospheres: size (μm) ± SD: 170.0 ± 8.32 (unsorted cells), 176.1 ± 15.11 (CD338bright), 
176.5 ± 15.17 (CD338
low
) and 80.96 ± 7.03 (CD338
neg
). Third generation mammospheres: 
Any mammospheres were generated from  CD338
neg 
sorted cells. 
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3.1.7  Soft agar colony formation assays 
3.1.7.1  Soft agar colony formation assay with sorted cell subpopulations 
The soft agar colony assay is a commonly accepted  method to assess anchorage-independent 
growth and it is considered a hallmark of cancer cells. To evaluate the transformation 
potential of three cell populations differing in regards to their CD338 antigenic phenotype,  
cells were sorted out, cultured few days to allow cell recovery and plated in soft agar. As 
shown in figure 3.14, both ABCG2 bright and low populations gave rise to colonies, while 
ABCG2 negative were found to be poorly transformed. In details, CD338
+/bright 
and 
CD338
+/low
 cells formed 3450 ± 481 and 2695 ± 117 colonies respectively, while CD338
neg 
formed just 948 ± 90 colonies. It is important to consider that CD338
neg 
sorted population was 
contaminated by CD338
+/low 
cells (see section 3.1.2.2), giving likely an explanation to the few 
colonies observed. In conclusion, CD338 positive cells are transformed in contrary to the 
negative ones. 
 
 
 
 
 
 
 
 
Figure 3.14.  Soft agar colony formation assay with CD338
+/bright
, CD338
+/low 
and 
CD338
neg
 populations. CD338
+/bright
, CD338
+/low 
and CD338
neg
  cells were sorted out from 
HCC1937 cell line, put in adherent conditions for few days to allow cell recovery after cell 
sorting, and then used to perform the colony assay. Colonies were counted after 4 weeks. 
Number of colonies are indicated for 5 x 10
4 
plated cells (± standard deviation, n = 3). 
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3.1.7.2 Soft agar colony formation assay with unsorted cells treated with cross-linker 
In order to improve the cell sorting purity, I tried to use a covalent cross-linker able to 
stabilize the binding of 5D3 antibody to its CD338 antigen (see section 3.1.2.1). Surprisingly, 
sorted cells gave rise to any colonies in soft agar, suggesting that the linker actually do 
interfere with ABCG2 properties and that loss of ABCG2 activity avoids survival/growth in 
low adherent conditions (Figure 3.15). To address this question, we assessed the effect of 
ABCG2 depletion through RNA interference on the cell transformation potential. Among the 
five shRNA tested, four were successful as functionally judged by the ABCG2 down-
regulation (Figure 3.16a). shRNA A was excluded for a toxicity problem. I next sought to 
confirm these results through assessment of ABCG2 at the protein level. Surprisingly, in all 4 
knockdown cells just CD338
bright
 cells disappeared, while CD338
low
 cells were still present 
(Figure 3.16b). This data indicated that, although the silencing was efficient (78%-92%), it 
was not enough to completely inhibit the synthesis of ABCG2 surface protein, avoiding 
further investigation on the role of ABCG2 in cell transformation. 
 
 
 
 
 
 
 
 
Figure 3.15. Effect of cross-linker on colony formation ability of unsorted cells. Unsorted 
cells were detached and divided in two aliquots. One was pre-incubated with cross-linker 
before CD338 staining and the other was not (see Materials & Methods). Then cells were 
used to perform the colony assay. Colonies were counted after 3 weeks. Number of colonies 
are indicated for 5 x 10
4 
plated cells (± standard deviation, n = 3). 
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Figure 3.16. Suppression of mRNA and surface protein expression by shRNA/ABCG2. 
(a) Relative mRNA expression levels of ABCG2 in knockdown cells, as estimated by qPCR. 
The level of mRNA expression in the parental HCC1937 cell line was set = 1.0 for reference 
purposes. NT= HCC1937 cells infected with viral particles that had not been transfected with 
any shRNA constructs; B to E = shRNA/ABCG2 clones cells. HPRT1 was used as a reference 
gene. (b) FACS analysis of ABCG2 surface protein expression. Just CD338
bright
 cells (red 
events) were decreased from 1% (of the total cell line) in NT cells (left panel) to 0.1% in 
silenced cells (right panel). 
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3.1.8  Tumorigenic assays 
3.1.8.1 Increase of CD338
bright 
cells in NOD/SCID mice 
To evaluate the tumorigenicity of the HCC1937 cell line, I either injected subcutaneously 
2×10
6 
or
 
4×10
5 
HCC1937 cells into the left and right flanks of four NOD/SCID 
immunocompromised mice, respectively. Tumor tissues were excised, digested to single cell 
suspensions and analyzed by flow cytometry (see Materials and Methods). Percentages of 
CD338
bright
 cells were determined in viable (SYTOX
-
) human (HLA-ABC
+
) epithelial 
(EpCAM
+
) gated tumor-derived cells (Figure 3.17b). The CD338
bright
 subpopulation  was 
enriched  in tumor-derived cells in comparison with the parental cell line  and mammosphere-
derived cells: about 40% (mean ± SEM: 37.50 ± 1.079) in tumor tissues, 1.4% in adherent cell 
line and  9.7% in mammospheres (Figure 3.17a,c). To compare the tumorigenicity of CD24
hi 
and CD24
-
 cells, an equivalent number of cells of both populations were injected in the left 
and right flanks of 5 NOD/SCID mice, respectively. Three mice were injected with 5x10
5
 
cells and 2 mice with 5x10
4
 cells. There was not a significant difference in the tumorigenicity 
of the two CD24 populations but, interestingly, tumor tissues originated from CD24
hi
 cells 
contained a significantly higher percentage of CD338
bright
 cells than tumor tissues originated 
from CD24
-
 cells (mean ± SEM: 55.25 ± 3.425 and 40.50 ± 0.500, respectively; p<0.05; 
Figure 3.18). This data confirm the correlation between CD24 and CD338 in HCC1937 cell 
line (see section 3.1.1.1 and figure 3.2). To compare the tumorigenicity of CD388
bright 
and 
CD338
neg
 cells, equal numbers of the two sorted cell subsets were similarly injected in the left 
and right flanks of 2 NOD/SCID mice, respectively. Consistently, a difference in tumor 
growth was observed between the two populations, the CD388 negative being indolent or 
giving rise to slow proliferating tumor.  Although the number of animals is too low to 
consider these results as significant, these data suggested that CD388
bright 
 cells are more 
tumorigenic than CD338
neg
 cells. I repeated these xenograft experiments by sorting the three 
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CD338
bright
 CD338
low 
and CD338
neg 
subpopulations and injecting them in nude mice (see 
section 3.1.8.2). Interestingly, tumor tissues originated from CD388
bright
 cells in NOD/SCID 
mice contained the highest percentage of CD338
bright
 cells between all tumors originated in 
NOD/SCID mice (i.e. tumors from total cell line and tumors from CD24
hi 
and CD24
neg 
sorted 
cells), whereas tumor tissues originated from CD388
neg
 cells contained the lowest one (90% 
and 35%, respectively; Figure 3.18). 
 
Figure 3.17. Expression of CD338 in tumors originated from unsorted HCC1937 in 
NOD/SCID mice. (a) Two different numbers of HCC1937 cells (2×10
6 
and
 
4×10
5
)  were 
injected subcutaneously into the left and right flanks of NOD/SCID mice, respectively. Dot 
plots show the percentages of CD338
bright
 cells in the cell suspensions obtained from digestion 
of tumor tissues. (b) Gating strategy used to analyze by flow cytometry the expression of 
CD338 in xenografts. Percentages of CD338
bright
 cell subpopulation were determined in viable 
(SYTOX
-
), human (HLA-ABC
+
), epithelial (EpCAM
+
) gated cells. (c) The histogram shows 
the percentage of  CD338
bright
 cells in adherent cell line, mammospheres from unsorted cell 
line, mammospheres from CD24
-
, CD24
hi
, CD24
hi
/CD338
-
, CD24
hi
/CD338
+
 sorted cells,  and 
in tumor tissues from unsorted cell line.  
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18. Expression of CD338 in tumors originated in NOD/SCID mice from sorted 
populations. Upper panels: flow cytometry analysis of tumor tissues originated from CD24
hi
 
and CD24
-
 sorted cell populations. Lower panels: flow cytometry analysis of tumor tissues 
originated from CD338
bright 
and CD338
-
. Percentages of CD338
bright
 cell subpopulation were 
determined in viable (SYTOX
-
), human (HLA-ABC
+
), epithelial (EpCAM
+
) gated cells. 
Tumor tissues originated from CD388
bright
 cells contained the highest percentage of 
CD338
bright
 cells (90%), whereas tumor tissues originated from CD388
neg
 cells contained the 
lowest one (35%). 
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3.1.8.2 Injection the three CD338 sorted subpopulations in nude mice 
Results of CD388
bright 
and CD338
neg
 sorted cell injections in NOD/SCID mice, suggested that 
CD388
bright 
cells are more tumorigenic than CD338
neg
 cells. These data were not statistically 
significant due to the low number of injected mice. I repeated the xenograft experiments by 
sorting the three CD338
bright
 CD338
low 
and CD338
neg 
subpopulations and injecting them in fad 
pats of nude mice. 12 mice, 4 for each of the three populations, were injected with sorted 
populations (10
4
 cells in each mouse). CD338
low
 sorted cells were the most tumorigenic (4/4 
for CD338
low 
versus 2/4 for CD338
bright
 and 2/4 for CD338
neg
, Table 4). As a control, unsorted 
HCC1937 cells were injected  (2x10
6
). Surprinsigly, most of the tumor-derived cells 
displayed an antigenic phenotype of luminal progenitor, i.e. EpCAM
+
/CD49f
+
 (Figure 3.19) 
and a CD338
low
 antigenic phenotype. This result is different from that previously obtained 
from injection of unsorted cells in NOD/SCID mice, where tumor-derived cells displayed a 
heterogeneous CD338 antigenic phenotype (Figure 3.17, panel a). 
 
Table 4. Tumorigenicity of CD338
 
bright, low and negative sorted populations in nude mice 
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Figure 3.19. Flow cytometry analysis of tumor originated from unsorted HCC1937 cells. 
Eight weeks after the injection, tumor was excised, digested to a single cell suspension and 
analyzed by flow cytometry. Tumor contained 40% of viable cells (DAPI
-
). 80% of viable 
cells were positive for the human marker HLA-ABC (red events), whereas 20% were negative 
(yellow events). Most human cells displayed an antigenic phenotype of luminal progenitor 
(EpCAM
+
/CD49f
+
, left panel). Almost all human cells were CD338
low
 (right panel). 
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3.1.9 Expression analysis of stemness genes, EMT inducers and epithelial/mesenchymal 
markers in CD338 sorted cells 
In breast cancer the epithelial-mesenchymal transition is highly related to tumor-initiating cell 
phenotype and basal subtype. So, I decided to explore the expression of stemness genes, EMT 
inducers and epithelial/mesenchymal markers in CD338
bright
 and CD338
neg
 sorted cell 
subpopulations. I chose as epithelial/mesenchymal markers E-cadherin and vimentin 
respectively, as stemness genes Sox2, Sox9, Oct4 and FUT4, and as EMT inducers Slug, Zeb1, 
Zeb2, Twist1. As shown in figure 3.20, results of RT-qPCR analysis of these genes were not 
significant. Particularly, some genes were differentially expressed in comparison to the total 
unsorted HCC1937 cell line, used as control, but the differences were not strong. For 
example, Sox2 and Sox9 displayed the highest expression in CD338
bright
 sorted cells, but their 
expression level was not strongly different to that of HCC1937 total cell line. The highest 
gene expression increase in CD338
bright 
sorted cells was that of Zeb2 (2.8), but it does not 
seem significant because there is an increase, even if less strong, also in CD338
neg
 sorted 
cells. Surprisingly, Oct4 displayed the highest expression in CD338
neg
 sorted cells. 
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Figure 3.20. Gene expression analysis of CD338 sorted and silenced cells. Relative mRNA 
expression levels of epithelial/mesenchymal markers, stemness genes and EMT inducers in 
CD338 bright and negative sorted populations, as estimated by qPCR. The level of mRNA 
expression in the parental cell line (unsorted) was set = 1.0 for reference purposes. HPRT1 
was used as a reference gene. 
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3.2 DISCUSSION 
 
The CSC model suggests that cancers arise from cells that can be defined, by analogy with 
totipotent stem cells, as cancer stem cells (CSCs) displaying self-renewal and differentiation 
potentials, to give rise to the phenotypically diverse cancer cell populations. However, the 
origin of CSCs is currently elusive. They could either originate from the malignant 
transformation of a stem/progenitor cell through the deregulation of the normally tightly 
regulated self-renewal program, or from transformation of committed cells through 
dedifferentiation of mature cells that reacquire some stem cell-like features including a self-
renewal potential.  
Breast cancer is the first human carcinoma for which a putative cancer stem cell 
subpopulation (BCSCs, breast cancer stem cells) has been isolated at the basis of its 
CD44
+
/CD24
-/low
 antigenic phenotype (Al-Hajj et al., 2003). The high heterogeneity of breast 
cancers fuels the actual debate on the cell at origin of the different subtypes of tumors. While 
a hierarchical model has been proposed, suggesting that luminal, basal and claudin-low 
subtypes arise from luminal progenitors, basal progenitors and stem cells respectively (Prat & 
Perou, 2009; Prat et al., 2010; Perou 2011), a flow of recent observations suggests that it 
might be more complex than previously thought. The identification of cells at the origin of 
BRCA1-tumors constitutes a first, and likely not unique, example of such a complexity. The 
most frequent tumors arising in BRCA1 germ-line mutation carriers have morphological 
features similar to those described in basal-like cancers. They indeed display a triple negative 
and basal-like phenotype as defined by immunohistochemistry or expression arrays (Foulkes 
et al., 2004; Lakhani et al., 2005; Sorlie et al., 2003). Initial pathological and histological 
studies of BRCA1 mutant breast tumors thus suggested that these cancers may arise from 
basal/myoepithelial cells (Liu et al., 2008). However, unexpectedly, recent studies rather 
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demonstrate that they originate from luminal progenitors (Lim et al 2009; Prat et al., 2010; 
Molyneux et al., 2010; Proia et al., 2011). Furthermore, neoplastic transformation often 
associates with a cell dedifferentiation process, as exemplified by the development of claudin-
low tumors upon aberrant expression of Ras and Twist in luminal committed cells (Morel et 
al., 2012). To ascertain the cell at origin of the various breast cancer subtypes, a first need is 
undoubtedly to affine the antigenic phenotype of the different cell subpopulations including 
the breast cancer stem cells. The ESA
+
CD44
+
CD24
-
 antigenic phenotype, originally identified 
by Clarke’s group, has been shown to be restricted to tumor initiating cells of certain breast 
cancers (Honeth et al., 2008). According to this finding, Meyer and colleagues showed that 
both CD44
+
CD24
-
 and CD44
+
CD24
+
 cell populations sorted from ER (Estrogen Receptor) 
negative breast tumors are tumorigenic in murine xenograft models, indicating that xenograft 
initiating cells are not always restricted to the CD44
+
CD24
-
 cell population (Meyer et al., 
2010). Although CD44
+
CD24
-
 tumorigenic cells may not display stemness features, these 
findings could also reveal the existence of CSCs displaying an antigenic phenotype different 
of the reported CD44
+
CD24
-
 phenotype. These studies, among others, thus question the 
relevance of CD44 and CD24 in identifying BCSCs. Obviously, there is an urgent need of 
additional markers to further discriminate the BCSCs.  
To identify novel BCSC markers, I focused my work on basal-like breast tumors because of 
two types of evidences: 1) these tumors, particularly the BRCA1 mutated basal-like breast 
cancers, have been proposed to arise from luminal progenitors (Lim et al., 2009; Molyneux et 
al., 2010; Lindeman and Visvader 2010; Perou, 2011); 2) Basal-like breast cancers do not 
homogeneously contain a CD44
+
/CD24
-/low
 cell population (Honeth et al., 2008; Meyer et al., 
2010). These and other studies led me to consider basal-like breast cancers, and the 
corresponding cell lines, as appropriate targets to identify CSCs with a phenotype different 
from the classical CD44
+
/CD24
-/low  
phenotype.  
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I particularly focused my attention on the basal-A BRCA1 mutated cell line HCC1937, 
established from a primary non-metastatic IDC (Invasive Ductal Carcinoma), as these cells 
were previously reported to include a CSC population that do not display a CD44
+
/CD24
-/low 
antigenic phenotype (Hwang-Verslues et al., 2009). In support of this view, by performing a 
wide flow cytometry characterization of several breast cancer cell lines, I found that the 
surface marker CD338/ABCG2 is heterogeneously expressed and displayed a higher 
expression level in CD24
+
 than in CD24
- 
cell subpopulation of the HCC1937 cell line. 
Furthemore, I found an almost complete overlap between side population and CD338 
overexpressing. Given that CD338/ABCG2 has been reported to be highly expressed in 
stem/progenitor cells and that the side population phenotype is known to be associated to 
stem/progenitor cells (Zhou et al., 2001; Cai et al., 2004), I thus reasoned that HCC1937 cell 
line could contain a putative CD24
+
CD338
+
 CSC subpopulation. This would confirm the 
presence, found by Hwang-Verslues, in the HCC1937 cell line of CSCs that do not harbor a 
CD44
+
/CD24
-/low 
antigenic phenotype.  
Mammosphere formation assays confirmed the presence of cancer cells with stem cell-like 
properties in the CD24+ population, and enrichment in CD338 in these cells. The enrichment 
in CD338 overexpressing cells in mammospheres and the overlap between SP and CD338 
overexpressing cells are coherent with the enrichment in SP cells in mammopsheres 
previously reported by Dontu (Dontu et al., 2003). The positive correlation between CD338 
and CD24 was further confirmed by the observation that, among the CD24 positive cells, 
those overexpressing the stem cell marker CD338 were able to form mammospheres with 
higher efficiency than CD338 negative cells.  
Although ABCG2 has been reported to be the major mediator of side population, on the other 
hand, it should be noted that only a fraction of the side population cells expresses ABCG2 
(Watanabe et al., 2004). Both side populations and stem/progenitor cells express additional 
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ABC transporters (Lechner et al., 2002; Hirschmann-Jax et al., 2004).  This could provide a 
first explanation of the partial overlap between side population and CD338 overexpressing 
cells in HCC1937 cell line. 
Taken together, flow-cytometry analysis, examination of side population and mammosphere 
formation assays support the conclusion that CD338 might constitute a novel antigen, likely 
more reliable than CD24, to isolate BCSCs at least in such a cell line. 
Unfortunately, use of this antigen has revealed some unexpected difficulties. Indeed, flow-
cytometry performed with the monoclonal anti-CD338 antibody 5D3, revealed a gradient of 
expression of cell surface antigen rather than a negative and positive cell subpopulations. This 
consequently complicates the isolation of the cell populations and reduces their purity.  The 
purity of a cell sorting is even more affected when sorted cells are rare, e.g. cancer stem cell 
populations, technically requiring to sort cells during long periods of time, and further 
complicated when the binding of the antibody to the surface antigen is not stable. As the 
CD338
bright 
cell population constitutes 1% of the HCC1937 cells, these technical difficulties 
were obvious. Furthermore, 5D3 binding to its extracellular epitope strongly depends on the 
conformation of ABCG2 (Ozvegy-Laczka et al., 2005), making the binding particularly 
unstable. Attempts to stabilize the antibody-antigen interaction with a protein cross-linker 
(PMPI, p-Maleimidophenyl isocyanate) were successful, significantly increasing the purity of 
CD338
bright
 cell sorted subpopulation (from 50-70% to 90-95%). Unfortunately, the crosslink 
of the transporter turned out to down-modulate its activity as demonstrated by the lack of 
colonies when unsorted cells were plated on soft agar. Although disappointing, these 
experiments likely highlight the key role of the transporter for the transformation potential of 
the cells, a hypothesis that we failed to address through RNA interference due to the limited 
efficiency of the shRNAs employed.  
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Nonetheless, taking benefit of LSR II, a third cell subpopulation expressing an intermediate 
level of CD338 has been unveiled. HCC1937 cells are thus constituted of three populations 1) 
CD338
+/bright
 expressing CD338 at high level and consisting just in 1% of the total cell line; 2) 
CD338
neg
 not expressing CD338 and representing about 20% of the total cell line; 3) 
CD338
+/low 
expressing CD338 at an intermediate level and consisting in about 79% of the 
total cell line. Despite the fact that this cytometer is not an analyzer, thanks to it, the three cell 
populations could be sorted out with a FACSAria cell sorter to assess their functional 
properties. 
Colony soft-agar assays demonstrated that CD338 positive cells are the only subpopulations 
displaying a transformation potential. Hwang-Verslues et al. found that CD24
+
 cells of 
HCC1937 cell line form more colonies than CD24
-
 cells in soft agar assay. As we observed 
that CD338 positive cells also overexpress CD24,
 
we conclude from the soft agar colony 
assays that CD24
+
CD338
+
 cells constitutes the only subpopulation of the HCC1937 cell line 
displaying a transformation potential. When xenografted in NOD/SCID and nude mice, 
CD338 negative were confirmed to be indolent while the CD338 positive were tumorigenic. 
This observations strengthen our conclusion that ABCG2 specifically map CSCs. To date, 
numerous studies have been conducted to analyze (i) ABCG2 expression in stem cells and 
human tumors and (ii) its activity as transporter in relationship to the SP phenotype. 
Conversely, there are still very few studies assessing the tumorigenic potential of ABCG2+ 
cells in comparison to ABCG2- ones. Patrawala and colleagues found that, although ABCG2 
preferentially mark proliferating cells, ABCG2 positive cells are not more tumorigenic than 
the corresponding ABCG2 negative cells (Patrawala et al., 2005). The conflict of our results 
with those of Patrawala could be explained by the different models used in the two studies. 
Patrawala and colleagues used cell lines from different types of tumors and they chose MDA-
MB-435 as breast cancer cell line. MDA-MB-435 is a basal-B cell line, so it belongs to a 
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molecular subtype different from that of HCC1937 cell line, i.e. basal-A. The difference of 
our results with those of Patrawala et al. could also be explained by the fact that a single 
marker is not sufficient to identify stem cells and the combination of CD24 and CD338 is 
likely to be more stringent. This is also supported by the observation that tumorigenic assays 
performed with CD24
hi 
and CD24
-
 sorted cells did not reveal any significant differences in the 
tumorigenicity of the two CD24 populations. Clearly, CD24 cannot be used on its one to 
identify stem cells, whereas CD338 in this regard is more relevant and the combination of the 
two antigens is likely to provide a better segregation. Our results also suggest a relationship 
between stem-like and tumorigenic properties of HCC1937 cells, as long as similar results 
have been obtained from mammosphere and xenograft assays. Actually, mammosphere assays 
revealed that, among CD24
+
 cells, those overexpressing CD338 displayed a higher 
mammosphere forming efficiency, and xenograft assays revealed a high tumorigenic potential 
for CD338 positive cells in comparison to CD338 negative ones, but not for CD24 positive 
cells in comparison to CD24 negative ones. Nonethelesss, a positive correlation between 
CD24 and CD338 was confirmed by the increase of CD338
bright
 in tumor tissues originated 
from CD24
hi
. The relevance of CD338 to isolate stem-like/tumorigenic cells from HCC1937 
cell line, was also confirmed by tumorigenic assays performed with the unsorted cell line, as 
CD338
bright
 subpopulation was strongly enriched in HCC1937-derived tumors in comparison 
with the parental cell line.   
Asymmetric division is one of the main properties of stem cells (Boman et al., 2007; 
Morrison and Kimble 2006). The analysis of CD338
bright
 and CD338
low
 sorted sub-
populations, after maintaining them in culture for several weeks, revealed that the antigenic 
phenotype of CD388
low
 cells remained stable and homogeneous, whereas CD338
bright
 cells 
gave rise to bright and low cells suggesting a filiation from CD338
bright 
cells to CD338
low 
cells.  
Our results are in agreement with the findings that, in several tumor cell lines, in just ~1% of 
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the ABCG2+ dividing cells, ABCG2 segregated asymmetrically to mainly one daughter cell 
(Patrawala et al., 2005). This observation suggests that just some ABCG2+ expressing cancer 
cells (1%, so a very few cells) might be undergoing asymmetrical cell division. Moreover, it 
has been recently reported that ABCG2+ cells purified from human hepatocellular carcinoma 
cell lines showed evidence for self-renewal, generating both ABCG2+ and ABCG2− 
progenies during subculture, and a higher proliferative activity (Zen et al. 2007). Furthermore, 
ABCG2 is known to be down-regulated during hematopoietic stem cell differentiation and is 
expressed at a low level in mature cells compared with progenitor cells (Zhou  et al. 2001; 
Scharenberg et al. 2002). The same phenomenon also occurs in human neural, retinal and 
embryonic stem cells (Islam et al. 2005; Bhattacharya et al. 2007; Apati et al. 2008). The 
highly regulated expression of ABCG2 suggests that ABCG2 may play a regulatory role in 
maintaining stem cells in an undifferentiated state. Considering that ABCG2 acts as an efflux 
pump, it is also possible that expression of ABCG2 in human progenitor cells critically expels 
substrates that are necessary for lineage differentiation, thereby blocking stem cell 
differentiation. We also found that CD338
low 
cells in tumors originated from unsorted 
HCC1937 cells display an antigenic phenotype of luminal progenitors, i.e. EpCAM+/CD49f+. 
This result, together with the observation that CD338
bright
 cells generate CD338
bright
 and 
CD338
low
 cells in subcultures, strongly supports the hypothesis that CD338
low
 cells could 
constitute the progeny of the most immature CD338
bright
 cells, and in particular, the luminal 
progenitor cells likely blocked at this stage of development. This hypothesis would also 
explain the fact that CD338
low
 cells constitute the most part of HCC1937 cell line (79%). The 
weak purity of CD388 negatively sorted out cell population avoided us performing filiation 
experiments with this subpopulation; thus, we can just hypothesize that CD338
neg
 cells could 
constitute the progeny of CD338
low
 population and so the most differentiated cells, as also 
suggested also by their low mammosphere-forming efficiency. Figure 3.21 shows a possible 
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model of filiation between  CD338
bright
, CD338
low
 and CD338
neg
  cell subpopulations in 
HCC1937 cell line. This model would be in agreement with that proposed by Lim et al. who 
found an increased number of luminal progenitors in breast tissue from BRCA1 mutation 
carriers. Indeed, HCC1937 is a cell line established from a BRCA1 mutated basal-like breast 
cancer.   
 
 
 
Figure 3.21. Schematic representation of the possible filiation between the different CD338 
cell subsets in the HCC1937 cell line 
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Obviously, to conclude that CD338 might constitute a novel antigen reliable to isolate BCSCs 
from this subtype of breast cancers, our results should be extended to other BRCA1 mutated 
basal-like cell lines and then tested directly on human breast cancer tissues.  Actually,  the 
accumulation of CD338
low
 cells in HCC1937 cell line could also be the result of in vitro 
selection. In that case, the fact that after several weeks in culture CD338
bright
 sorted cell 
population contain also CD338
low
 cells, could be explained through an in vitro equilibrium 
between the two populations. Anyway, the different possibilities about the nature of CD338
low
 
cells in the HCC1937 cell line, could be elucidated by their in vivo behavior and so by the 
analysis of tumors originated from the sorted cell subpopulation. Indeed, if tumors originated 
from CD338
low
 sorted cells would contain only CD338
low
 cells, the first hypothesis that 
CD338
low
 cells would constitute the luminal progenitor cells likely blocked at this stage of 
development, could be confirmed. The model proposed by Lim et al. would then be 
extrapolated to the HCC1937 cell line. Another possibility is that tumors originated from 
CD338
low
 sorted cells contain both CD338
low
 and CD338
bright
 cells, this could indicate the 
ability of CD338
low
 cells to dedifferentiate in vivo thus generating the more immature 
CD338
bright 
cells. Ongoing experiments would help us to discriminate between these two 
possibilities. 
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3.3 MATERIALS AND METHODS 
 
3.3.1  Cell Culture 
The human breast cancer continuous cell line HCC1937, was purchased from the American 
Type Culture Collection (ATCC, Rockville, MD, USA). The cells were initially cultured in 
RPMI (Sigma-Aldrich Corporation, St. Louis, Missouri, USA), 10% fetal bovine serum (FBS; 
Hyclone, Logan, UT, USA) and 1% Ultraglutamine 1 (Lonza Verviers, Belgium). Later, due 
to their high metabolism, cells were cultured in IMDM (Invitrogen), 20% FBS (Gibco). 
To obtain the high numbers necessary for cell sorting cells were grown in 15 cm dishes in a 
humidified atmosphere of air containing 5% CO2 until confluence, then they were detached 
by trypsin/EDTA (Sigma-Aldrich Corporation, St. Louis, Missouri, USA). 
To follow the expression of CD338 after cell sorting, cell subpopulations sorted out from 
HCC1937 cell line were seeded and grown in 12-well, 6-well or 10 cm dishes. The human 
breast cancer continuous cell lines MCF7, Hs578T and BT-20 were cultured in DMEM, 10% 
FBS. During the study, all cell lines were periodically tested for the absence of bacteria, fungi 
and mycoplasma contaminations. 
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3.3.2 Flow cytometry analysis and cell sorting 
3.3.2.1 Expression analysis of surface markers in breast cancer cell lines 
Antigens and antibodies  
 On breast cancer cell lines mentioned above, MCF-7, HCC1937, BT-20 and Hs578, the 
expression of 30 surface antigens was evaluated: CD9 (p24), CD10 (CALLA), CD24 (HSA), 
CD26 (DPPIV), CD29 (β1 integrin), CD44 (H-CAM), CD47 (Rh-associated protein), CD49b 
(α2 integrin), CD49f (α6 integrin), CD54 (ICAM), CD55 (DAF), CD59 (MIRL), CD61 (β3 
integrin), CD66b (CEACAM8), CD66c (CEACAM6), CD81 (TAPA1), CD90 (Thy1), CD105 
(Endoglin), CD133 (prominin1), CD151 (PETA-3), CD164 (MUC-24), CD165 (AD2), 
CD166 (ALCAM),  CD184 (CXCR4), CD200 (OX2), CD227 (MUC1), CD324 (E-Cadherin), 
CD326 (EpCAM), CD338 (ABCG2), CD340 (Her2). These surface antigens include 
molecules involved in processes such as cell adhesion, migration, apoptosis, metastasis, cell 
signalling, proliferation, differentiation and molecules known to be stem cell and/or cancer 
stem cell markers (Table 2, Results section). 
Multi-color flow cytometry was performed by using anti-human monoclonal antibodies 
(MoAbs) that were conjugated with phycoerythrin (PE), fluorescein isothiocyanate (FITC), 
phycoerythin-Cy7 (PE-Cy7) or Alexa Fluor 647. PE-conjugated MoAbs against CD10, CD29, 
CD54, CD55, CD59, CD61, CD151, CD166, CD200, CD340 and FITC-conjugated MoAbs 
against CD9, CD26, CD47, CD49b, CD49f , CD66b, CD66c, CD81, CD90, CD164, CD165, 
CD227, CD324 and CD326 were from BD Biosciences and BD Pharmingen, (San Jose, CA); 
PE-coniugated MoAb against CD133 from Miltenyi Biotech (Auburn, CA, USA); 
AlexaFluor647-conjugated MoAb against CD24,  PE-Cy7-conjugated MoAb against CD44 
and PE conjugated MoAb against CD338 from Biolegend (San Diego, CA, USA); PE-
conjugated MoAb against CD184 from Immunotech (Marseille, France); PE-conjugated 
MoAb anti-CD105 from Serotec (Kidlington, Oxford, UK). 
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Sample preparation 
For expression analysis of the 30 surface markers a four-color flow cytometric strategy was 
performed. In particular, cells were stained with MoAbs anti-CD24-AlexaFluor 647 and anti-
CD44-PECy7 combined with pairs of antibodies, conjugated with other two different 
fluorochromes, against surface antigens explored as potential novel BCSC markers (Table 5). 
Thus, each experiment consisted of 14 tubes, each containing MoAb anti-CD24-
AlexaFluor647, MoAb anti-CD44-PE-Cy7, one PE-conjugated  and one FITC-conjugated 
antibody.  In all expression analysis experiments, an analysis buffer (AB) was used to prepare 
cells: RPMI without red phenol (Invitrogen), 1-2% FBS (Gibco), 10U/ml DNase (Sigma-
Alderich). After enzymatic detachment from saturated cultures, cells were counted, 
resuspended in the analysis buffer at 5x10
5
 for 100μl and stained by incubation at 4°C for 20 
minutes with the appropriate amount of above mentioned MoAbs. After staining, all samples 
were washed twice with the analysis buffer, centrifuged and resuspended in 0.5 ml of FACS 
buffer (FACS Flow Sheat Fluid, BD Biosciences) for FACS analysis. A few minutes before 
FACS acquisition cells were incubated at RT in the dark with a vital dye (SytoxBlue or DAPI, 
Invitrogen ), to exclude dead cells from the analysis. In all experiments, a negative control 
was prepared to exclude the signal background caused by the cellular autofluorescence. The 
negative control consisted in HCC1937 cells treated with the same procedure but except the 
antibody staining. (see 6.2 of Flow Cytometry Appendix). 
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Table 5. Four-color flow cytometry panel for expression analysis of surface markers in breast 
cancer cell lines 
Tube FITC PE PE/Cy7 AlexaFluor647 
1 CD49f CD338 CD44 CD24 
2 CD90 CD133 CD44 CD24 
3 CD47 CD200 CD44 CD24 
4 CD227 CD10 CD44 CD24 
5 CD324 CD29 CD44 CD24 
6 CD66c CD61 CD44 CD24 
7 CD49b CD184 CD44 CD24 
8 CD164 CD340 CD44 CD24 
9 CD9 CD54 CD44 CD24 
10 CD26 CD55 CD44 CD24 
11 CD81 CD151 CD44 CD24 
12 CD66b CD59 CD44 CD24 
13 CD165 CD166 CD44 CD24 
14 CD326 CD105 CD44 CD24 
 
 
Cytometers 
The samples were analyzed by using FACSAria I flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ). FITC, PE and PE-Cy7 fluorescences were determined by a 488nm 
excitation line and detected by 530/30nm, 585/42nm and 780/60nm filters, respectively. 
AlexaFluor-647 fluorescence was determined by a 633nm excitation line and detected by a 
660/20nm filter (see sections 6.1 and 6.4 of Flow Cytometry Appendix). For each sample run, 
10,000 to 20,000 events were recorded and analyzed. In the initial phase of the study, I could 
use only the 488nm laser of FACSAria I flow cytometer to excite PE which was the 
fluorochrome conjugated to the anti-CD338 MoAb. This laser allows to discriminate only 
CD338 positive and negative cells. Later, I had the opportunity to analyze the expression of 
CD338 with the 561nm laser of BD LSR II four-laser flow cytometer (see section 6.4 of Flow 
Cytometry Appendix). This laser is able to better discriminate the different PE fluorescences, 
so it allowed to distinguish, among the CD338 negative cells, the real negative cells from a 
subpopulation of cells expressing CD338 at low level, named CD338
+/low
. 
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Analysis strategy of cytometric data 
The  samples were analyzed by using the FACSDiva software (Becton Dickinson, Franklin 
Lakes, NJ). To define the target cell population to analyze for the expression of 28 surface 
markers, we used a three gating strategy: first, to exclude dead cells and debris, cells were 
gated on a two physical parameters dot plot measuring forward scatter (FSC) vs side scatter 
(SSC) (see sections 6.1 and 6.2 of Flow Cytometry Appendix). Doublets were excluded by 
gating cells on FSC-Height vs FSC-Area dot plots (see section 6.2 Flow Cytometry 
Appendix)  and finally, also to exclude dead cells, we gated Sytox Blue or DAPI negative 
cells. The expression level of each surface marker in the different cell lines was reported as 
percentage of positive cells in Count vs FITC- or PE-CD histograms. Furthermore, I also 
defined the expression level of each antigen in the different CD44/CD24 subpopulations, 
since each FITC-CD or PE-CD antibody was combined with anti-CD44 and anti-CD24 
antibodies. 
 
3.3.2.2 Cell sorting of CD24 and/or CD338 cell subpopulations of HCC1937 cell line 
Cell expansion for cell sorting 
For each cell sorting, HCC1937 cell line was expanded until enough cells were available to 
obtain the appropriate number of sorted cells necessary for the downstream experiments. 
During the whole study, the limiting subpopulation consisted in cells expressing CD338 at 
high level (CD338
bright
 cells) that represent only 1% of the total HCC1937 cell line. So, to sort 
the different CD338 subpopulations, cells were expanded up to 150x10
6  
in 150x25mm cell 
culture dishes. This level of cell expansion allowed me to obtain a number of CD338
bright
 
sorted cells enough to perform downstream experiments such as soft agar assays, 
mammosphere assays and RT-qPCR. 
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Sample preparation 
During the preparation of cells for cell sorting, a sorting buffer (SB) was used: RPMI without 
red phenol (Invitrogen), 1-2% FBS (Gibco) 10U/ml DNase (Sigma-Alderich) and 2.5mM  
EDTA.  After enzymatic detachment from saturated cultures, cells were counted, resuspended 
at 50x10
6
 for ml in the SB and stained by incubation with the appropriate amount of CD338 
and/or CD24 at 4°C for 1h. To increase the purity of the cell sorting, before CD338 staining, 
cells were incubated with 1mM PMPI (p-Maleimidophenyl isocyanate) (Thermo Scientific 
Pierce), a cross-linker able to stabilize the epitope of CD338 antibody. After staining, samples 
were washed twice with the SB, and resuspended at 20x10
6
 for ml of the SB. Cells were 
aliquoted in 5ml polypropylene tubes by filtration with 50μm filters (Partech). Finally, cells 
were incubated few minutes at RT in the dark with a vital dye, SytoxBlue (Invitrogen) or 
DAPI (Invitrogen).  
 
Cell sorting 
Live cell sorting (see section 6.3 of Flow Cytometry Appendix) experiments were performrd 
using  BD FACSAria I with 100µm nozzle. PE fluorescence of CD338 was determined by a 
488nm excitation line and detected by 585/42nm filters, whereas AlexaFluor 647 fluorescence 
of CD24 was determined by a 633nm excitation line and detected by 660/20nm filter. In the 
initial phase of the study, just CD338 positive and negative subsets were usually sorted and 
further studied. Later, I performed three-ways cell sorting, that means three different 
subpopulations, CD338
+/bright
 CD338
+/low
 and CD338
neg
, were sorted. Sorted cells were 
collected in a collecting buffer (CB) - RPMI without red phenol (Invitrogen), 20% FBS 
(Gibco) 10U/ml DNase (Sigma-Alderich) and 2% penicillin/streptomycin (Invitrogen) - and 
used to perform mammosphere assays, soft agar colony assays, RT-QPCR and in vivo 
tumoigenic experiments. 
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3.3.3 Side population in HCC1937 cell line 
Progenitor/stem cells are able to actively extrude the fluorescent Hoechst 33342 dye, and so, 
they are negative for this dye. The negative-Hoechst 33342 cell population is called Side 
Population (SP) and ABCG2 seems to be one of the major mediators of side population. To 
study the side population in HCC1937 cell line, the method described by Goodell et al. was 
used. Cells (1x10
6
 cells/ml) were incubated in pre-warmed medium (RPMI without red 
phenol 20% FBS). Freshly prepared Hoechst-33342 (Sigma-Alderich) at 5μg/ml was added 
and cells were incubated for 90 min at 37°C. In each experiment one sample set was treated 
with 5μM Reserpine which inhibits efflux of the Hoechst 33342 and therefore functions as a 
negative control. After incubation, cells were centrifuged at 2000 rpm for 5 minutes at 4°C,  
resuspended in ice-cold RPMI and stained with 2μg/ml Propidium Iodide (to exclude dead 
cells from analysis) by incubation in the dark at 4°C for 10 minutes. Finally, cells were 
washed once with ice-cold RPMI and analyzed by FACSAria I flow cytometer. The Hoechst 
dye was excited at 375 nm by the Near UV laser option and its fluorescence was measured by 
dual wavelength: 450/20 nm BP filter (Hoechst blue) and 675 EFLP optical filter (Hoechst 
red, see section 6.1 of Flow Cytometry Appendix). The side population was gated as defined 
in Goodell et al. (Goodell et al., 1996). 
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3.3.4 Mammosphere Formation assays 
For mammosphere generation, HCC1937 cells were seeded in 96-well low attachment plates 
(Corning, New York, USA) at the concentration of 1000 cells/well for primary culture, and at 
100 cells/well in the following passages. Cells were grown in a serum-free mammary 
epithelial growth medium (MEBM, Lonza, Verviers, Belgium) supplemented with B27 
(Invitrogen, Carsbal, CA), 20 ng/ml EGF, 20 ng/ml bFGF and 4 μg/ml  heparin (all from 
Sigma, St. Louis, MO). Mammosphere were collected by gentle centrifugation (1000 rpm) 
and dissociated enzimatically (5 min in trypsin/EDTA) and mechanically (26 Gauge needle) 
and then processed for experiments. 
 
3.3.5 Soft Agar Colony Assay 
Anchorage-independent cell growth is one of the hallmarks of cell transformation. The soft 
agar colony assay is a common method to monitor anchorage-independent growth, which 
measures proliferation in a semisolid culture media after 3-4 weeks by manual counting of 
colonies and it is considered the most stringent assay for detecting malignant transformation 
of cells. Pates were prepared with a coating of 0.75% low-melting agarose (Lonza) by mixing 
equal volumes of 1.5% agar and 2x growth medium (IMDM). Cells were detached with 
trypsin, resuspended in growth medium and counted. An overlaid suspension of cells in 
0.45% low-melting agarose was prepared by mixing equal volumes of 0.9% agar and 2x 
growth medium (IMDM) with cells (5×10
4
 cells/well). Plates were incubated for 3-4 weeks at 
37°C and colonies were then counted under microscope. Experiments were performed in 6-
well dishes and also in 12-well dishes to improve the ability of sorted cells to form colonies.  
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3.3.6 Gene expression analysis by RT-qPCR 
Total RNA was prepared using an RNeasy mini kit (Qiagen). RNA was reverse transcribed 
using the DyNAmo cDNA synthesis kit (FINNZYME) with RNase H+ Reverse Transcriptase 
and random hexamer primers. Real-time quantitative PCR was carried out using the Universal 
Probe Library (UPL) technology based on only 165 short hydrolysis probes. Within the 
human trascriptome, each probe binds to approximately 7000 trascripts but only one specific 
transcript is detected at a time in a given PCR assay, as defined by the set of chosen PCR 
primers. In table 6 are reported the UPL probes and the sequences of the primers used for all 
the analyzed genes. LightCycler TM System instrument was used (Roche Applied Science). 
Results were displayed as relative levels of genes per HPRT1. Each experiment was repeated 
at three times. 
 
Table 6. UPL probes and primer sequences for analyzed genes 
Gene Primer Forward Primer Reverse UPL 
Twist 1 ggc-tca-gct-acg-cct-tct-c cct-tct-ctg-gaa-aca-atg-aca-tct 88 
Zeb 1 aac-tgc-tgg-gag-gat-gac-ac tcc-tgc-ttc-atc-tgc-ctg-a 57 
Sox 2 tgc-tgc-ctc-ttt-aag-act-agg-ac cct-ggg-gct-caa-act-tct-ct 35 
Oct 4 ctt-tga-ggc-tct-gca-gct-tag ctg-ctt-tgc-ata-tct-cct-gaa-g 69 
Sox 9 gta-ccc-gca-ctt-gca-caa-c tcg-ctc-tcg-ttc-aga-agt-ctc 61 
Slug tgg-ttg-ctt-caa-gga-cac-at gtt-gca-gtg-agg-gca-aga-a 7 
FUT 4 cgt-gga-cga-ctt-ccc-aag gtt-gcg-gtc-gag-gaa-aag 52 
E-Cadherin ccc-ggg-aca-acg-ttt-att-ac gct-ggc-tca-agt-caa-agt-cc 35 
Vimentin gac-cag-cta-acc-aac-gac-aaa gga-gca-tct-cct-cct-gca-at 39 
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3.3.7 Injection in mice and processing of xenografts 
All animal experiments were conducted in accord with accepted standards of human animal 
care. To compare the tumorigenicity of CD24
hi
 vs CD24
-
 and of CD338
bright
 vs CD338
-
 sorted 
populations, female NOD/SCID mice aged 4 weeks (Charles River laboratories) were 
subcutaneously injected. In particular, three NOD/SCID mice were injected with 5x10
5
 
CD24
hi
 vs CD24
-
 cells into the left and right flanks respectively and two NOD/SCID mice 
were injected with 5x10
4
 CD24
hi
 vs CD24
-
 cells into the left and right flanks respectively. 
Three NOD/SCID mice were injected with 3 different numbers of CD338
+
 vs CD338
-
 cells 
into the left and right flanks, respectively. To compare the tumorigenicity of CD338
bright
, 
CD338
low
 and CD338
neg
 sorted populations, Swiss/nude mice aged 8 weeks (Charles River 
laboratories) were injected into a fat pad of mammary gland. In particular, four mice for each 
of the three populations, were injected with 10
4 
cells. In all xenograft experiments, injections 
of mice with unsorted HCC1937 cells were used as positive controls. Cells from unsorted cell 
line or sorted cell subpopulations were counted, resuspended in PBS and Matrigel (1:1; BD 
Biosciences) and injected into mice. Tumor formation was assessed by palpation once a week. 
Animals were sacrificed as soon as tumor size reached 1.5 cm in diameter or before. Tumor 
tissues obtained were minced into <1mm pieces, dissociated in an enzymatic solution [CO2-
independent medium complemented with: collagenase A 3 mg/ml (Sigma), 
penicillin/streptomycin 2%, 100U/ml Hyaluronidase IV, 2% glutamine, 5% FBS and DNase 
0.1mg/ml (Roche)]  and incubated at 37°C for 60 minutes with gentle agitation. Single cell 
suspensions obtained were analyzed by flow cytometry after staining with antibodies against 
the surface antigens of interest. 
 
 
 
95 
 
3.3.8 Silencing ABCG2 in HCC1937 cells using lentiviral vector-based shRNA 
The strategy of the silencing 
To silence ABCG2 I used the MISSION product line of Sigma Alderich that is a viral vector-
based RNAi library against mouse and human genes. The libraries consist of bacterial 
glycerol stocks harboring sequence-verified shRNA lentiviral plasmid vectors for mouse and 
human genes cloned into the pLKO.1-puro vector (Figure 3.22).  MISSION shRNA clones 
are constructed within the lentivirus plasmid vector, pLKO.1-puro, followed by 
transformation into Escherichia coli. Bacterial cultures, provided as a frozen bacterial 
glycerol stocks, may be amplified from the glycerol stocks for use in purification of the 
shRNA plasmid DNA. Subsequently, viral particles can be produced in packaging cells 
(HEK293T) by co-transfection with compatible packaging plasmids. pLKO.1-puro vectors 
contain bacterial (ampicillin) and mammalian (puromycin) antibiotic resistance genes for 
selection of inserts in either bacterial or mammalian cell lines. Upon co-transfection of the 
plasmids, all required sequences are available to produce and package a viral particle 
containing the transgene of interest. Only the region between the viral LTRs of the transfer 
vector is packaged within the viral capsid. Compared to siRNA and other vector-based 
systems, pLKO.1-puro provides solutions for long-term knockdown and phenotypic 
observation, transduction of difficult or sensitive cell lines (non-dividing cells or primary 
cells). 
We purchased five MISSION shRNA clones against ABCG2 from Sigma-Aldrich. These five 
21-nucleotide shRNA duplexes from five different parts of the human ABCG2 mRNA 
(GenBank accession number NM_004827) were designed using the MISSION search 
database  (Zhang et al., 2009). The shRNA sequences tested are presented in table 7. 
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Table 7: Sequences of shRNA/BCRP clones 
A CCGGGCCTCGATATTCCATCTTCAACTCGAGTTGAAGATGGAATATCGAGGCTTTTTG 
B CCGGGCAACAACTATGACGAATCATCTCGAGATGATTCGTCATAGTTGTTGCTTTTTG 
C CCGGCCTTCTTCGTTATGATGTTTACTCGAGTAAACATCATAACGAAGAAGGTTTTTG 
D CCGGGCTGTGGCATTAAACAGAGAACTCGAGTTCTCTGTTTAATGCCACAGCTTTTTG 
E CCGGCCTGCCAATTTCAAATGTAATCTCGAGATTACATTTGAAATTGGCAGGTTTTTG 
 
 
 
 
 
Figure 3.22: Physical map of lentiviral ABCG2 shRNA transfer verctor construct 
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Purification of shRNA plasmid DNA 
To purify the shRNA plasmids, bacteria from glycerol stocks were cultivated on LB agar to 
be amplified and to allow to pick single colonies for each shRNA. Single colonies were 
picked and inoculated into 2ml of LB/ampicillin (100μg/ml) and, 12h after, were transferred 
into 200ml LB/ampicillin and incubated at 37°C in agitation for over-night. shRNA plasmid 
DNA was purified using the PureYeld Plasmid Maxiprep System kit (Promega). 
 
Generation of lentiviral particles 
Of the many methods to introduce DNA into mammalian cell cultures, the calcium phosphate 
method is one of the most widely used because it is inexpensive, simple, and suitable for a 
range of different cell types (Graham & van der Eb, 1973). Lentivirus particles were 
generated by calcium phosphate co-transfection of 293T cells by three vectors: 
1) pLKO.1-puro with one of the five shRNAs 
2) pCMVdeltaR8.91 for the expression of the key structural viral packaging genes (Gag-
Pol-Tat-Rev) 
3) phCMVG-VSVG for the expression of the envelope 
The “Mammalian CalPhos transfection kit” of Clontec, providing H2O sterile, CaCl2 2M and 
HBSS 2X, was used to perform the co-trasfection. Particularly, the “transfection mix” was 
first prepared with: 13.2 µg of pLKO.1-puro with one of the five shRNAs, 10.2 µg of the 
vector pCMVdR8.91, 2.64 µg of the vector phCMVG-VSVG, 86.8 µl CaCl2 , and H2O to 
reach a total volume of 700μl. Then, 700 µl of Hank’s balanced salt solution (HBSS) were 
added drop by drop by vortexing the “transfection mix”. Transfection mixes were incubated at 
RT for 25 minutes and then spread on 293T cells. Six hours after transfection, cells were 
gently washed twice with PBS 1X, and 6ml of fresh medium was added. The day after, 
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medium was changed with 6ml of fresh one to have at the end, after filtration, 5 ml of virus 
for infection. 
 
Infection of HCC1937 cells with lentiviral particles and cell selection 
Two days after transfection, the viral supernatants were filtred twice with 0.45 µM filters. 
Polybrene was added (5 µg/ml) to increase the efficiency of infection. It is a cationinc 
polymer that acts by neutralizing the charge repulsion between the virons and cell surface. 
The viral supernatants were put on HCC1937 cells (5 ml in 10cm dish). Finally, the medium 
was changed after six hours. 48h after infection, cells were divided by adding puromycin 
1μg/ml to select infected cells, since pLKO.1-puro vector contains the mammalian puromycin 
antibiotic resistance gene. 
 
3.3.9 Statistical analysis 
All measures and experiments were carried out at least three times. Data obtained from 
mammospheres assays and xenografts experiments were analyzed through t-test and one-way 
analysis of variance (ANOVA). Differences with values of p<0.05 were considered 
significant. All statistical analyses were carried out using GraphPad Prism software (version 
5.00). 
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IV. PART 2: 
Cytometric and biochemical characterization of breast cancer cells from  
patient-derived breast cancer tissues* 
 
Results from the PART 1 of the present thesis strongly support the presence, in the basal-A 
BRCA1-mutated cell line HCC1937, of a BCSC subpopulation bearing the phenotype 
CD44
+
CD24
+
CD338
bright
. To conclude that CD338 might constitute a novel antigen reliable to 
isolate BCSCs from basal-like breast cancers, our results should be extended to human tissues 
from patients with basal-like breast cancers. Considering this perspective, we carried out a 
complementary work to standardize the flow-cytomertic methods to study primary cultures 
established from human breast cancer tissues. While accomplishing this standardization, we 
have also carried out a wide cytometric and biochemical characterization of cell cultures 
established from patient-derived breast tissue samples. To evaluate whether cell cultures 
maintain the cellular heterogeneity found in primary tissues, we compared breast cancer cell 
cultures from primary tissues with standard breast cancer cell lines through the analysis of 
expression profiles of a panel of surface markers. We found that in vitro culturing of breast 
cancer cells leads to the selection of myoepithelial/basal breast cancer cells. Furthermore, we 
demonstrated that breast cancer cell cultures preserve inter-tumor heterogeneity and express 
stem/progenitor markers that can be identified, quantified and categorized by flow cytometry.  
 
 
*Leccia F, Nardone A, Corvigno S, Del Vecchio L, De Placido, Salvatore F, and Veneziani BM. (2012). 
Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial 
phenotypes. Cytometry-A 81(11): 960-972.  
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4.1 RESULTS 
 
4.1.1 CD44/CD24 expression profile in breast cancer cell cultures 
4.1.1.1 Percentages of CD44
+
/CD24
-/low 
and CD44
+
/CD24
-
 phenotypes 
Cells purified from breast tissues are categorized according to the cell surface expression of 
CD44 and CD24, which distinguishes CD44
-
/CD24
+
 cells (luminal epithelial cells) from 
CD44
+
/CD24
-
 cells (basal cells) (Shipstin et al., 2007); however, a considerable heterogeneity 
in CD44 and CD24 expression was reported both between and within breast tumors (Honeth 
et al., 2008). To determine whether these markers could be used to classify luminal and basal 
breast cancer cells in cell cultures, we analyzed a panel of patient-derived breast cancer cell 
cultures (n=7) and compared them with standard cell lines previously classified on the basis 
of gene and protein expression profiling (Neve et al., 2006; Shipstin et al., 2007; Keller et al., 
2010).  Although all cell cultures displayed a CD44
+
CD24
-/low 
phenotype regardless of tumor 
subtype, biparametric dot plots (Figure 4.1a) of CD44-PE-Cy7 vs CD24-AlexaFluor647 show 
that the prevalence of CD24
-/low 
cells varied among samples. MCF7, MCF10A, cultures #4 
and #7 show a low prevalence of this phenotype (Figure 4.1b). Although, from an evaluation 
of the pattern of the dot plots, it emerges a clear-cut different CD44/CD24 expression pattern 
between the MCF7 cell line and all the other cell lines and samples, quantitative analysis of 
CD44
+
CD24
-
 vs CD44
+
CD24
+
 cells of cultures #4 and #7 displayed a trend similar to that of 
MCF7 and MCF10 cells, with a high percentage of CD24
+
 cells (79.0%, 89.9%, 89.1% and 
99.0%, respectively, Table 10 and Figure 4.1b). Thus, the difference of the CD44/CD24 dot 
plot in MCF7 cell line in comparison to all the other cell lines and samples, is not due to 
different percentages of CD44
+
/CD24
-/low 
cells, but rather to a very low intensity of CD44 
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expression in MCF7 cells (see section 6.2 of Flow Cytometry Appendix for the difference 
between percentage and intensity in the analysis of cytometric data). 
 
4.1.1.2 Intensity of CD44 and CD24 expression 
We used mean fluorescence intensity (MFI) analyses to estimate the number of CD44 and 
CD24 molecules per cell (Figure 4.1c,d). CD44 expression was very low in MCF7 cells (MFI 
= 15, linear scale range: 0-10,000), and high (> 1000) in all the breast cancer cell cultures, as 
well as in MCF10A, Hs578T and MDAMB231 cells. As shown in Figure 4.1d, intensity of 
CD24 expression was low in all cell lines and cultures (1 ≤MFI≤ 109; MFI linear scale range: 
0-10,000). Within this low-range of intensity, CD24 expression was very low in the MCF10A 
cell line and #5 cell culture (28 and 1 respectively), whereas it was higher in Hs578T and 
MCF7 cell lines and in culture #4 (MFI> 50). The prevalence of a CD24
-/low
 phenotype and 
the low intensity of CD24 expression could indicate the in vitro loss of luminal phenotype in 
cell cultures established from patient-derived breast cancer tissues. 
 
4.1.2 Morphology and mammosphere formation 
One of the associations in cell line collections is the relationship between the transcriptional 
phenotype and distinctive biological characteristics such as morphology. Adherent cultures of 
breast cancer cells had a mixed morphology with few polygonal cells and a prevalence of 
spindle-like cells (Figure 4.2 upper side of each pair of panels). Mammary gland progenitor 
cells can be propagated through mammosphere culture. We evaluated whether the patient-
derived cell cultures possessed the ability to form spheres. To this aim, we passed the cells 
(1000/well) to low attachment plates with low serum (0.5% FBS); within 2-3 days the cells 
formed aggregates that had the characteristic morphology of floating mammospheres (Figure 
4.2, lower side of each pair of panels). Fixing the number of seeded cells and the time to 15 
102 
 
days after seeding in non-adherent conditions, if the number of mammospheres formed is 
similar, we expect that the diameter of the spheres is inversely related to the number of death 
cells and thus it represents a surrogate index of stem cell survival in non-adherent conditions. 
We measured the diameter and the number of spheres per well. Although all the cell lines and 
breast cancer cell cultures formed spheres, the average diameter of aggregates (Figure 4.2, 
histogram) is heterogeneous, ranging from 50 to 180 µm. Breast cancer cell cultures #4 (mean 
= 50µm) and #1 (mean = 180µm) formed the smallest and largest size mammospheres, 
respectively. The mean diameters of the remaining cultures were: culture #2=116 µm, #3=75 
µm, #5=100 µm, #6=120 µm, and #7=94 µm. 
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Figure 4.1. CD44 and CD24 expression in breast cancer cell cultures and cell lines.  (A) 
The expression of the two markers is presented on a biparametric dot plot CD44-PE-Cy7 vs 
CD24-AlexaFluor647 for each breast cancer cell culture and cell line. Vertical and horizontal 
markers delineate the quadrants used to identify the different CD44/CD24 subsets and were 
set with the appropriate negative control. (B) Percentages of CD44
+
/CD24
- 
(quadrants Q1 in 
dot plots of panels A) and CD44
+
/CD24
+
 (quadrants Q2 in dot plots of panels A) cell 
subpopulations. (C) Number of CD44 molecules expressed on the cell surface. The histogram 
reports the mean fluorescence intensity (MFI, range: 0-10.000) of CD44. (D) Number of 
CD24 molecules expressed on the cell surface of the breast cancer cell cultures and cell lines. 
The histogram shows the mean fluorescence intensity (MFI, range: 0-10.000) of CD24.  
 
 
104 
 
 
 
Figure 4.2. Mammospheres formation and size. Phase-contrast microscopy of adherent 
breast cancer cells #1-7 (upper side of each pair of panels) and the corresponding 
mammospheres (lower side of each pair of panels). Scale bar 100µm. The graph depicts the 
average diameter of mammospheres; digital images were analyzed with AxioVision software, 
the diameter of ten spheres per well was measured and the means are reported in µm. The 
mean of samples ranged  from 50 µm to 150 µm; sample #1, 180 µm; sample #2, 116 µm; 
sample #3, 75 µm; sample #4, 50 µm; sample #5, 100 µm; sample #6,120 µm, sample #7, 94 
µm. The mean standard error was < 5%. 
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4.1.3 Immunophenotypic characterization of breast cancer cell cultures 
The 28 surface markers were selected based on their potential to distinguish stem cell 
populations (CD24, CD44, CD49f, CD133, CD200 and CD326), to mediate cell adhesion and 
migration (CD9, CD29, CD49b, CD49f, CD61, CD184), metastasis (CD44 and CD184) and 
signaling (CD66c) (Table 8). We used a four color flow cytometric strategy to measure the 
expression of these surface markers based on a flow cytometry panel in which cells were 
stained with MoAbs anti-CD24 and anti-CD44 and with antibodies against all the other 
analyzed surface antigens (Table 12, Materials and Methods). We used a three gating strategy 
to define the target cell population which should be analyzed for the expression of surface 
markers. (Figure 4.3).  
Tables 9 and 10 show the percentages of cells expressing surface markers in all breast cancer 
cell lines and patient-derived cultures. All markers showed a unimodal profile in all cell lines 
and cell cultures, which is indicative of homogeneity of a cellular population within the 
sample (see section 6.2 of Flow Cytometry Appenix). An exception to the general unimodal 
pattern was the expression of CD105 (endoglin) in sample #1 (Figure 4.3). Ten out of 28 
surface markers were homogeneously expressed, at high or low level, in all cell lines and cell 
cultures (Table 9). These were CD29 (β1 integrin), CD55 (DAF), CD59 (MIRL), CD66b 
(CEACAM8), CD66c (CEACAM6), CD81 (TAPA1), CD151 (PETA-3), CD165 (AD2), 
CD166 (ALCAM) and CD324 (E-cadherin). On the other hand, 18/28 surface markers were 
heterogeneously expressed (Table 10). CD90 (Thy-1), which is expressed on normal basal 
cells but not on luminal cells (Donnenberg et al., 2010), was highly expressed in all cell 
cultures and in the Hs578T cell line (100% of positive cells), not expressed in the luminal 
MCF7 cell line, and intermediately expressed (60.4%) in the basal MCF10A cells. CD10 
(CALLA), a marker of myoepithelial cells, was highly expressed in all cell cultures (100% of 
positive cells) and poorly expressed in the MCF7 and MDAMB231 cell lines. CD326 
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(EpCAM) and CD227 (MUC-1), two key markers of luminal epithelial cells, were highly 
expressed in the luminal MCF7 cell line, 100% and 85.3% of positive cells respectively. 
Conversely, CD326 and CD227 expression was low or absent in the Hs578T and 
MDAMB231 basal-B/mesemchymal cell lines and intermediate in the MCF10A cell line. In 
all patient-derived cell cultures, CD326 was  expressed at very low levels, whereas the 
expression of CD227 was 42.4% and 40.0% for samples #2 and #7, respectively. CD54 
(ICAM-1), a molecule whose function is required for invasion of metastatic breast cancer 
cells, is highly expressed either in the cell cultures  (from 85.1% to 99.7% of positive cells) 
and in the cell lines (MCF7=94.7%, MDA=83%, HS578T=100%, MCF10A=64.0%), 
although differences are greater than 5%, and we thus considered it as a heterogeneously 
expressed marker. In conclusion, immunophenotipic characterization of patient-derived breast 
cancer cell culture confirm the in vitro loss of luminal phenotype, as also suggested by the 
CD44/CD24 expression profile (section 4.1.1). 
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Table 8. Molecular identity and function of the cell surface markers analyzed   in breast 
 cancer cell lines and cell culturer  from patient-derived breast tissue samples. 
 
CD  Molecule Function References 
CD9 P24 Cell adhesion and migration Nishida 2009 
CD10 CALLA Antigen overexpressed on many tumors Iwaya 2002 
CD24 HSA Adhesion and spread of metastatic tumors Al-Hajj 2003 
CD26 DPPIV Exopeptidase, tissue restructuring Pro 2004 
CD29 β1 integrin Adhesion to matrix proteins Charafe-Jauffret 2009 
CD44 H-CAM Sppression of apoptosis, metastasis Al-Hajj 2003 
CD47 Rh-associated protein Cell activation, apoptosis, cell spreading Manna 2004 
CD49b α2 integrin Cell adhesion to collagen and laminin Langsenlehner 2006 
CD49f α6 integrin Cell surface signaling Cariati 2008 
CD54 ICAM Cell adhesion, immune reactions Rosette 2005 
CD55 DAF Protection against complement Ikeda 2008 
CD59 MIRL Protection from complement-mediated lysis Babiker 2005 
CD61 β3 integrin Cell-surface mediated signaling Charafe-Jauffret 2009 
CD66b CEACAM8 Cell adhesion, transmembrane signalling Lasa 2008 
CD66c CEACAM6 Cell adhesion, transmembrane signalling Lasa 2008 
CD81 TAPA-1 Response to antigens Yáñez-Mó 2009 
CD90 Thy-1 Proliferation and differentiation Yamazaki 2009 
CD105 ENG (Endoglin) Angiogenesis, vessel wall integrity Henry 2011 
CD133 Prominin 1 Unknown Wright 2008 
CD151 PETA-3 Cell adhesion Sadej 2009 
CD164 MGC-24 Adhesion and homing Havens 2006 
CD165 AD2 Unknown Seon 1984 
CD166 ALCAM Adhesion, organ development Kulasingam 2009 
CD184 CXCR4 Increased expression in mammospheres Krohn 2009 
CD200 OX2 Immunosuppression Kawasaki 2007 
CD227 MUC1 Response to hormones and cytokines Stingl 2009 
CD324 E-Cadherin Cell adhesion, tumor suppression Prasad 2009 
CD326 EpCAM Cell adhesion Stingl 2009 
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Figure 4.3. Representative strategy of flow cytometry analysis of breast cancer cell 
culture #1. (A,B,C):  gating strategy used to remove debris, cell clusters and dead cells. (A) 
To exclude dead cells and debris, cells were gated on a two physical parameters dot plot 
measuring forward scatter (FSC) vs side scatter (SSC) (see section 6.2 of Flow Cytometry 
Appendix); (B) Then doublets were excluded by gating cells on FSC-Height vs FSC-Area dot 
plots (see section 6.2 of Flow Cytometry Appendix); (C) Finally,  Sytox Blue negative cells 
were gated.  (D) Surface marker expression on cells gated as described of #1 breast cancer 
cell culture. The expression of each antigen is represented on a frequency distribution 
histogram (count vs FITC or PE signal) (see section 6.2 of Flow Cytometry Appendix). The 
vertical marker on each histogram used to detect the antibody-positive cells was established 
using the appropriate negative controls. 
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Table  9.  Antigens homogeneously expressed* in breast cancer cell lines and cell cultures  
from patient-derived breast tissue samples 
 
Negative or very lowly expressed antigens† 
 Cell line Breast cancer cell culture  
CD MCF7 MDAMB231 Hs578T MCF10 #1 #2 #3 #4 #5 #6 #7 
66b 0.1‡ 1.4 0.7 1.7 0.4 0.0 0.3 0.3 0.0 0.0 0.8 
66c 0.4 1.5 0.7 4.0 0.9 0.0 0.2 3.5 0.0 0.0 1.2 
165 0.1 0.4 3.9 1.9 1.6 0.4 0.6 1.5 4.0 7.0 6.5 
324 4.2 2.1 3.7 2.5 0.5 3.3 0.5 1.2 0.4 0.0 7.0 
 
Highly expressed antigens† 
 Cell line Breast cancer cell culture  
CD MCF7 MDAMB231 Hs578T MCF10 #1 #2 #3 #4 #5 #6 #7 
29 100.0 100.0 99.9 100.0 100.0 100.0 99.9 100.0 99.7 100.0 100.0 
55 100.0 99.1 99.8 99.5 100.0 98.8 99.2 99.6 96.2 100.0 100.0 
59 100.0 99.8 98.9 100.0 100.0 100.0 100.0 100.0 99.6 100.0 100.0 
81 100.0 99.4 99.5 98.7 100.0 100.0 100.0 99.6 99.8 100.0 99.9 
151 100.0 99.8 99.8 94.9 99.5 99.8 100.0 100.0 99.8 100.0 100.0 
166 100.0 100.0 100.0 90.1 100.0 100.0 98.9 100.0 100.0 100.0 98.5 
 
*Molecules with expression differences  ≤ 5% were considered homogeneously expressed, 
whereas those with differences  > 5% were considered heterogeneously expressed. 
†Negative or expressed at very low level:  ≤ 7%; highly expressed : ≥ 99.1% 
‡Percentage of cells within each cell line or primary culture that were antibody-positive and 
therefore expressing the indicated antigens. The percentages of antibody-positive cells were 
calculated by comparison with the appropriate negative control. 
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Table 10. Antigens heterogeneously expressed* in breast cancer cell lines and cell cultures  
from patient-derived breast tissue samples 
 
CD  MCF7  MDA 
MB231  
Hs578T  MCF10 #1  #2  #3 #4 #5 #6 #7 
9  99.9 †  55.1  0.2  99.5 16.6  74.4  9.5  2.8  42.2  36.7  98.0 
10  10.7  16.6  99.1  93.1 99.2  100.0  100.0  99.6  100.0  98.0  100.0 
24  89.1  31.1  45.5 99.0 47.5  54.6  37.3  79.0  0.0  60.0  89.9 
26  0.2  1.1  79.3  4.4 69.8  74.2  56.0  8.3  2.6  50.9  88.8 
44  71.0  98.0  100.0  99.9 100.0  99.8  100.0  100.0  100.0  100.0  100.0 
47  100.0  71.6  60.0  99.5 21.7  77.4  60.0  88.2  82.0  69.0  99.9 
49b  99.9  100.0  42.0  99.9 39.9  13.5  93.7  96.9  79.4  94.0  99.8 
49f  21.2 99.5 91.1  100.0 82.1 74.7 15.2 89.8 4.3 12.2 92.0 
54  94.7  83.0  100.0  64.0 99.4  85.1  92.7  99.7  85.4  91.0  97.7 
61  0.2  59.9  41.5  27.0 58.4  23.0  93.5  74.2  89.1  50.0  65.7 
90  0.3 6.7  100.0  60.4 100.0  100.0  100.0  99.5  100.0  100.0  100.0 
105  22.2  61.2  98.4  38.4 67.5  100.0  21.9  99.7  97.0  83.0  23.9 
133  72.0  22.6  92.9  18.0 33.3  45.9  13.9  1.8  41.3  90.0  1.5 
164  33.0  69.7  0.4  24.2 0.6  5.1  0.8  0.4  4.3  0.0  4.0 
184  0.9  11.6  12.6  41.0 2.4  11.9  5.0  1.7  7.3  6.0  11.0 
200  4.4  24.5  26.4  90.9 12.0  0.7  0.2  6.7  6.7  20.0  24.0 
227  85.3  1.7  2.3  33.8 3.2  42.4  3.3  3.2  0.0  2.0  40.0 
326  100.0  1.8  4.0  77.8 0.6  0.1  0.7  0.7  0.0  0.0  0.4 
 
*Molecules with expression differences  ≤ 5% were considered homogeneously expressed, 
whereas those with differences  > 5% were considered heterogeneously expressed. 
†Percentage of cells within each cell line or cell culture that were antibody-positive and 
therefore expressing the indicated antigens. The percentages of antibody-positive cells were 
calculated by comparison with the appropriate negative control. 
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4.1.4 Cell culture phenotype correlates with the myoepithelial/mesenchymal phenotype 
We used the non-parametric Spearman correlation test to compare the phenotypic 
heterogeneity of breast cancer cell cultures with that of control cell lines (Table 11). Although 
displaying heterogeneous expression of surface markers, cell cultures were strongly correlated 
with Spearman correlation coefficients (rs), which ranged from 0.7 to 0.9 (0.7 < rs > 0.9). All 
cell cultures were also strongly correlated with the cell line Hs578T (0.6 < rs > 0.9) and, even 
if to a lesser extent, to the MDAMB231 cell line and to the MCF10A (0.1 < rs > 0.6) cell line. 
They were not correlated with the MCF7 cell line (-0.3 < rs > -0.04, p>0.05). Since Hs578T 
and MDAMB231 are basal-B/mesenchymal cell lines, whereas MCF7 is a luminal cell line, 
these results further support the selection of basal/mesenchymal phenotype in patient-derived 
breast cancer cell cultures. 
 
4.1.5 Expression of epithelial/mesenchymal markers 
To determine whether patient-derived cultured cells expressed the epithelial or mesenchymal 
phenotype we immunoblotted for cytokeratins (CK), vimentin and SMA (Figure 4.4). CK18 
and CK19 are epithelial markers, whereas CK5, SMA and vimentin are 
myoepithelial/mesenchymal markers (Blick et al., 2008). Densitometric analysis, reported as 
percentage increase vs tubulin, showed that CK18 and CK19 were highly expressed, more 
than 0.5% increase, in MCF7 cells (2.08 and 1.9) and in culture #4 (1.05 and 1.3) (Figure 
4.4). CK5, SMA and vimentin were not expressed in MCF7 epithelial cells but present in the 
Hs578T, MDAMB231, MCF10 cell lines, and all the breast cancer cultures. Cultures #1, #4 
and #6 expressed high levels of SMA (>0.5% increase).  
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Table 11. Correlations between human breast cancer cell lines and cell cultures based on 
heterogeneously expressed surface markers 
 
  MCF7 MDA 
MB231 
Hs578T MCF10 #1 #2 #3 #4 #5 #6 
MDA 
MB231 
0.316*                 
Hs578T -0.215 0.214               
MCF10 0.443 0.577 0.125        
#1 -0.321 0.257 0.893 0.223            
#2 -0.096 0.187 0.778 0.225 0.817          
#3 -0.158 0.299 0.735 0.260 0.839 0.699        
#4 -0.065 0.463 0.822 0.429 0.872 0.799 0.798      
#5 -0.204 0.349 0.639 0.178 0.643 0.675 0.744 0.697    
#6 -0.042 0.270 0.831 0.244 0.801 0.724 0.867 0.802 0.779  
#7 0.034 0.334 0.512 0.604 0.699 0.689 0.807 0.728 0.604 0.707 
 
*Nonparametric Spearman correlation coefficient (rs).  
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Figure 4.4. Analysis of luminal and basal markers expression in breast cancer cell lines 
and cell cultures from patient-derived breast tissue samples. (a) Western blot of 
cytokeratin 18 (CK18), cytokeratin 19 (CK19), cytokeratin 5 (CK5), alpha smooth muscle 
actin (SMA) and vimentin (vim) in control cells Hs578T, MCF7, MDA-MB231, MCF10A 
and in sample cells #1, #2, #3, #4, #5, #6, #7. 30 µg of total protein extract were loaded. 
Tubulin was used as a loading control. (b) Densitometric analysis with Scion Image was 
performed with cytokeratin 18 (CK18) and cytokeratin 19 (CK19) (light bar), cytokeratin 5 
(CK5), alpha smooth muscle actin (SMA), vimentin (Vim) (dark bar), in control cells 
Hs578T, MCF7, MDA-MB231, MCF10A, and sample cells #1, #2, #3, #4, #5, #6, #7. Data 
were normalized for tubulin; standard error, not reported on graph, was < 10%. 
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4.2 DISCUSSION 
 
In vitro culture of human breast cancer cells usually leads to selection for basal/myoepithelial 
(Neve et al., 2006; Keller et al., 2010). We have immunophenotyped breast cancer cell 
cultures and cell lines for 28 surface markers to analyze the cell surface phenotype, and 
showed that a panel of CD antigens can be used to determine inter-tumor heterogeneity.    
To determine the cellular heterogeneity of tumors, we used a four-color flow cytometric 
strategy in which CD24 and CD44 stained cells were also stained with MoAb against two 
other antigens (Table 12, Materials and Methods section). The 28 surface markers were 
selected based on the potential to distinguish between cell types of epithelial or mesenchymal 
lineage or to identify putative cancer stem/progenitor cells. Every marker showed a unimodal 
profile in all samples, which indicates the lack of cellular subpopulations. The only exception 
to this general pattern is the expression of CD105 (endoglin) in sample #1, the significance of 
which requires further investigation. Flow cytometric analysis showed that 10 surface markers 
were homogeneously expressed in all cell lines and breast cancer cell cultures. Between these 
ten surface markers, some, such as CD324 (E-cadherin) displayed very low values, and 
others, such as CD166 (ALCAM), displayed high values. Particularly, four markers (CD66b, 
CD66c, CD165, CD324) displayed negative/low expression in all the cell lines and breast 
cancer cells tested. Every marker is involved in cell adhesion. CD66b and CD66c MoAbs 
react with CEACAM-8 and CEACAM-6, respectively. Members of the CEACAM family 
play a role in invasion and metastasis, are involved with cellular differentiation (Ilantzis et al., 
2002), and are expressed in breast cancer carcinomas (Esteban et al., 1994). CD324/E-
cadherin. E-cadherin functions as a tumor suppressor gene. In breast cancer, loss of E-
cadherin expression is a necessary component for invasion and metastasis (Peinado et al., 
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2007), and it is a marker of epithelial-mesenchymal transition (Blick et al., 2008). Reduction 
of CD324 (E-cadherin) expression is associated with breast carcinomas of basal-like and 
triple negative phenotype (Mahler-Araujo et al., 2008) and with the acquisition of cancer stem 
cell associated characteristics like increased CD44
+
/CD24
- 
ratio (Sigurdsson et al., 2011). On 
the othe hand, among the ten homogeneously expressed markers, six displayed homogenous 
high expression in all the cells, namely CD29 (beta1-integrin), CD55 (DAF), CD59 (MIRL), 
CD81 (TAPA1), CD151 (PETA-3) and CD166 (ALCAM). CD55 (DAF) and CD59 (MIRL) 
are two complement regulatory proteins expressed on cells to avoid autologous complement 
attack. In breast cancer, there is a high variability in complement regulatory protein 
expression, with some tumors expressing only one inhibitor, and others expressing various 
combinations of two or three inhibitors (Niehans et al., 1996). CD81 (TAPA1) and CD151 
(PETA-3) belong to the four-transmembrane domain (tetraspanin) family of proteins involved 
in regulating tumor cell motility and invasiveness, mainly through their effect on the adhesive 
and signaling function of integrin (Yànez-Mo et al., 2009). Integrin-tetraspanin complexes 
modulate tumor cell-cell and cell-substrate interactions (Stipp et al., 2010; Romanaska et al., 
2011). CD166 (ALCAM) is overexpressed in breast cancer metastases (Ihnen et al., 2011). 
High values of CD166 are associated  with high values of CD44 and either high or low values 
of CD24 (Stuelten et al., 2010). 
The homogeneous, low or high, expression of surface markers suggests that cell lines and 
breast cancer cell cultures share many of the molecular features of their acquired ability to 
grow in vitro, and acquired adaptation to culture conditions. This is in agreement with 
previous reports (Neve et al., 2006; Keller et al., 2010; Petersen et al., 2010). While the 
markers in the homogenously expressed group (Table 9, Results section) could be considered 
molecules ubiquitously expressed for the biological adaptation of cells to in vitro conditions, 
the heterogeneously expressed group (Table 10, Results section) is likely to consist of 
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molecules that identify cells of different origin. In agreement with others (Keller et al., 2010), 
we found that heterogeneity within each cell line and patient-derived breast cancer cell culture 
was remarkably restricted (unimodal profile), which could indicate that in vitro culturing 
enriches for cellular phenotypes that may represent the progeny of different stem/progenitor 
cells. On the other hand, we found that 18/28 antigens were heterogeneously expressed 
between all breast cancer cell lines and cultures. If the different distribution of marker 
expression is influenced by the culture conditions, then the expression profile patterns in the 
cell lines and breast cancer cell cultures would appear not to be related. We thus performed 
correlations using Spearman’s rank, on the base of heterogeneously expressed markers. We 
found no correlation of the patient-derived breast cancer cells with MCF7 cell line, a weak to 
moderate correlation with MDA-MB231 and with MCF10A, statistically significant 
correlations (p<0.001) with Hs578T and a strong statistically significant correlation within the 
different breast cancer cell cultures (Table 11, Results section). Since heterogeneity between 
breast cancer cell cultures does not depend on culture conditions because all the primary 
cultures undergo the same protocol of isolation, the flow cytometry analysis shows the 
potential to identify individual features of a breast tumor.  
Studies designed to define the cell of origin in experimental model systems report that 
mesenchymal stem cells, isolated from various normal and pathological tissues, show 
phenotypic heterogeneity (Chamberlain et al., 2007) and it has been suggested that they reside 
in virtually all postnatal tissues. The resulting cultures are morphologically heterogeneous; in 
fact, they contain cells ranging from spindle-shaped cells to polygonal cells and some 
cuboidal cells. Mesenchymal stem cells express a number of markers, none of which are 
specific to mesenchymal stem cells. Although many of these markers display variable 
expression due to differences in (i) tissue source, (ii) the method of isolation and culture, and 
(iii) species, it is generally agreed that adult human mesenchymal stem cells can express 
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CD44 (H-CAM), CD90 (Thy-1), CD105 (Endoglin), CD184 (CXCR4), various integrin 
molecules, such as CD49b (α2integrin), CD49f (α6integrin), CD29 (β1integrin), CD61 
(β3integrin), and other adhesion molecules including CD54 (ICAM) and CD166 (ALCAM) 
(Chamberlain et al., 2007). Within our breast cancer cell cultures, which were all CD44
+
, 
concomitant high expression of surface markers associated with the mesenchymal stem cell 
phenotype included CD10/CALLA, CD54/ICAM and CD90/Thy-1, and was paralleled by 
low expression of CD326-EpCAM.  
Breast cancers are broadly classified histopathologically by the expression of either luminal 
cytokeratins (CK18/19) or basal cytokeratins (CK5), SMA and vimentin (Sorlie et al., 2001); 
the categorization in subtypes is critical for the prediction of clinical outcome and treatment 
response. To refine the portrait of patient-derived breast cancer cell cultures, we examined 
whether the markers associated with myoepithelial/basal-like breast phenotype (CK5, SMA 
and vimentin) and those associated with luminal phenotype (CK18 and CK19) were 
differentially expressed based on culture conditions. Particularly, myoepithelial cells are cells 
from the basal layer, defined as cells expressing both epithelial markers and contractile 
proteins (Anbazhagan et al., 1998). These cells are distinguished from basal cells in 
multilayered squamous epithelium because they express proteins characteristics of 
mesenchymal cells, such as vimentin (Rønnov-Jessen et al., 1995), alpha SMA (Gusterson et 
al., 19982), and cytokeratins 5 (CK5, or basal cytokeratin) (Nagle et al., 1986). However, 
studies aimed at defining the cell of origin in breast tumors show that the expression of CK5 
is not restricted to myoepithelial cells in tissue cultures (Gusterson et al., 2005). We used 
western blot to evaluate the expression of these markers in all cell lines and breast cancer cell 
cultures. Although the overall levels of marker expression were different, all of the breast 
cancer cell cultures analyzed in this study expressed CK5, SMA and vimentin, all markers of 
basal/myoepithelial cells, as well as the basal-b/mesenchymal cell lines MDAMB231 and 
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Hs578T, whereas MCF7 do not. The majority of human breast cancers cell lines, were 
cytokeratin 18 (CK18) and cytokeratin 19 (CK19) positive, although expressing them at 
different levels. Conversely, all the breast cell cultures, excluding culture #4, were negative or 
weakly positive for CK19 and CK18. Taken together, results of immunophenotype and 
western blot analysis indicate that the patient-derived breast cancer cell cultures displayed a 
myoepithelial/mesenchymal phenotype. Our results, are in agreement with the in vitro loss of 
phenotype restricted to the luminal lineage (Keller et al., 2010). 
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4.3 MATERIALS AND METHODS 
 
4.3.1 Materials 
Standard medium consisted of minimal essential Dulbecco/Ham F12 (1:1) (DMEM/F12) 
(Sigma-Aldrich), supplemented with 2 mM glutamine (Sigma-Aldrich), P/S, 15 mM HEPES 
(Sigma-Aldrich) and 5% FBS. MCF-7, MDA-MB231, Hs578T and MCF10A were from 
ATCC (American Type Culture Collection). Multi-color flow cytometry was performed with 
anti-human monoclonal antibodies (MoAbs) that were conjugated with phycoerythrin (PE), 
fluorescein isothiocyanate (FITC), phycoerythin-Cy7 (PE-Cy7) or Alexa Fluor 647. PE-
conjugated MoAbs against CD10, CD29, CD49f , CD54, CD55, CD59, CD61, CD66c, 
CD151, CD166 and CD200, and FITC-conjugated MoAbs against CD9, CD26, 
CD47,CD49b, CD66b, CD81, CD90, CD164, CD165, CD227, CD324 and CD326 were from 
BD Biosciences and BD Pharmingen (San Jose, CA, USA); PE-conjugated MoAb against 
CD133 from Miltenyi Biotech (Auburn, CA, USA); AlexaFluor647-conjugated MoAb against 
CD24, and  PE-Cy7-conjugated MoAb against CD44 were from Biolegend (San Diego, CA, 
USA); PE-conjugated MoAb against CD184 was from Immunotech (Marseille, France); PE-
conjugated MoAb anti-CD105 was from Serotec (Kidlington, Oxford, UK). For western blot 
analysis the following MoAb CK5 (AE14) cod: sc-80606, CK19 (BA17) cod: sc-53258 and 
SMA (alpha Smooth Muscle Actin) (CGA7) cod: sc-53015 were diluted 1:200. The 
secondary antimouse antisera (sc-2005) were diluted 1:3000. The polyclonal antibodies used 
were as follows: pNeu (Tyr-1248)-R cod: sc-12352, diluted 1:100, CK18 (H-80) cod: sc-
28264 diluted 1:200, ER-alpha (HC-20) cod: sc-543 diluted 1:400 and EGFR (1005) cod: sc-
03 diluted 1:1000. The secondary anti-rabbit antisera (sc-2004) were diluted 1:3000. All the 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The 
monoclonal anti-Tubulin (clone DM 1A) code: T-9026 diluted 1:400 and vimentin (clone V9) 
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code: V-6630 diluted 1:1000 were from Sigma-Aldrich (Milan, Italy). All dilutions were 
made in TBS-Tween 20 (Thermo Fisher Scientific, Milan, Italy) with 5% non fat milk 
(Applichem, Darmstadt, Germany). 
 
4.3.2 Breast tumor specimens and cell culture conditions 
Tumor histotype, size, grading and markers including ER were determined with standard 
procedures, and HER2 was determined with HercepTest (Dako, Carpintera, CA, USA). The 
following data were retrieved from the pathology reports of each patient: patient #1, invasive 
lobular carcinoma (ILC), pT1  N0 (T = tumor size, N = lymph node involvement),  ER-positive 
(Estrogen Receptor alpha) (80%) and without c-erbB2 over-expression; patient #2, invasive 
ductal carcinoma (IDC) with a mucinous component, pT2 N0, ERα-positive  (80%) and c-
erbB2-negative; patient #3, IDC, pT1 N1, ERα-negative (<5%) and c-erbB2 overexpression 
(+++); patient #4, IDC, pT1 N1, ERα-positive (80%), and c-erbB2 overexpression (+++). 
Patient #5, IDC, pT2 N0, and ERα-negative, without c-erbB2 over-expression; patient #6, IDC 
arising from a contralateral recurrence, pT1c Nx, ERα-positive (>90%) and c-erbB2-negative; 
patient #7, IDC, pT1, N0, ERα-negative (<5%) and c-erbB2-negative. All patients had a high 
grade of malignancy. 
Breast cancer tissue specimens were collected, processed, cultured and frozen as cell 
suspension via standardized operative procedures for banking (Veneziani et al., 2007) and cell 
population expansion (Nardone et al., 2011). Control MCF-7, MDA-MB231, Hs578T and 
MCF10A were cultured in DMEM plus 10% FBS. Frozen cells were thawed, allowed to 
adhere and harvested 15-20 days in standard medium.  
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4.3.3 Mammosphere formation efficiency and size  
Cells were dissociated and seeded, 1000 cells/well, in ultra-low attachment surface 24 well 
plates (Corning) in DMEM/F12 plus 0.5% FBS medium, according to Dontu et al. The 
medium was renewed twice weekly. Mammospheres were cultured for 15 days and measured 
under an inverted microscope Axiovert 40 C (Zeiss, Milan, Italy) equipped with a Canon 
powershot A640 camera (Zeiss). Digital images were analyzed with AxioVision software 
(Zeiss).  
 
4.3.4 Flow cytometry analysis 
Cell suspensions were analyzed for the expression of 28 surface antigens, namely, CD9 (p24), 
CD10 (CALLA), CD24 (HSA), CD26 (DPPIV), CD29 (β1 integrin), CD44 (H-CAM), CD47 
(Rh-associated protein), CD49b (α2 integrin), CD49f (α6 integrin), CD54 (ICAM), CD55 
(DAF), CD59 (MIRL), CD61 (β3 integrin), CD66b (CEACAM8), CD66c (CEACAM6), 
CD81 (TAPA1), CD90 (Thy1), CD105 (Endoglin), CD133 (prominin1), CD151 (PETA-3), 
CD164 (MUC-24), CD165 (AD2), CD166 (ALCAM), CD184 (CXCR4), CD200 (OX2), 
CD227 (MUC1), CD324 (E-Cadherin), CD326 (EpCAM) (Table 8, Results section). We used 
a four color flow cytometric strategy to measure the expression of these surface markers 
(Table 12). Briefly, each experiment consisted of 13 tubes, each containing MoAb anti-CD24-
AlexaFluor647, MoAb anti-CD44-PE-Cy7, one PE-conjugated and one FITC-conjugated 
antibody against two of the other CD antigens to be analyzed. For all experiments, after 
enzymatic detachment from non-saturated cultures, cells were counted, resuspended at 5x10
5
 
in 100μl of PBS and stained by incubation at 4°C for 20 min with the appropriate amount of 
above the MoAbs in PBS. After staining, all samples were washed twice with PBS, pelletted 
and suspended in 0.5 ml of FACS buffer (FACS Flow Sheat Fluid, BD Biosciences) for 
FACS analysis. A few minutes before FACS acquisition, cells were incubated at room 
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temperature in the dark with a vital dye (SytoxBlue, Invitrogen) to exclude dead cells from 
the analysis. In all experiments, for each cell type, a negative control was treated with the 
same procedure but without antibody staining. This negative control represents the 
background caused by the cellular autofluorescence (see section 6.2 of Flow Cytometry 
Appendix). The samples were analyzed with a FACSAria flow cytometer and the FACSDiva 
software (Becton Dickinson, Franklin Lakes, NJ, USA). For each sample run, 10,000 to 
20,000 events were recorded and analyzed. We used a three gating strategy that is the same 
described in figure 4.3. 
 
Table 12. Four-color flow cytometry panel for expression analysis of surface markers 
in breast cancer cell lines and cell cultures  from patient-derived breast tissue samples 
 
Tube FITC PE PE/Cy7 AlexaFluor647 
1 CD164  CD49f  CD44  CD24  
2 CD90  CD133  CD44 CD24 
3 CD47  CD200  CD44 CD24 
4 CD227  CD10   CD44 CD24 
5 CD324  CD29  CD44 CD24 
6 CD66c  CD61  CD44 CD24 
7 CD49b  CD184  CD44 CD24 
8 CD9 CD54 CD44 CD24 
9 CD26  CD55  CD44 CD24 
10 CD81  CD151 CD44 CD24 
11 CD66b CD59 CD44 CD24 
12 CD165 CD166 CD44 CD24 
13  CD326 CD105 CD44 CD24 
 
Each experiment consisted of 13 tubes. Each tube contained the MoAb anti-CD24-
AlexaFluor647, the MoAb anti-CD44-PE-Cy7, one PE-conjugated and one FITC-conjugated 
antibody against two of all the other CD antigens to be analyzed. 
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4.3.5 Western blot analysis 
Whole cell extracts were obtained by lysing samples in 50 mmol/L of TRIS (pH 7.5), 100 
mmol/L of NaCl, 1% NP40, 0.1% Triton, 2 mmol/L of EDTA, 10 µg/mL of aprotinin, and 
100 µg/mL of phenylmethylsulfonyl-fluoride. Protein concentration was measured using the 
Bio-Rad protein assay (Bio-Rad Laboratories, Milan, Italy). Prestained molecular weight 
standards BenchMark were from Invitrogen (Milan). Proteins separated on the 
polyacrylamide gels were blotted on a nitrocellulose membrane (Protran, Whatman; 
Germany). The membrane was stained with Ponceau S (Sigma-Aldrich) to evaluate the 
success of transfer, and to locate the molecular weight markers. Free protein binding sites on 
the nitrocellulose were blocked with nonfat dry milk and a Tween 20/TBS solution. The 
membranes were washed and stained with specific primary antibodies and with secondary 
antisera conjugated with horseradish peroxidase diluted 1:3,000. The luminescent signal was 
visualized with the ECL Western blotting detection reagent kit (Amersham) and quantified by 
scanning with a Discover Pharmacia scanner equipped with a Sun Spark Classic Workstation. 
Scion Image version beta 4.0.3  software (Scion, Frederick, Maryland) was used to quantify 
signal intensity. 
 
4.3.6 Data analysis 
Each experiment was carried out 2–4 times and found to be reproducible. Human tissue 
samples were not pooled, therefore each sample served as its own control. Error bars are 
presented as standard error of the mean (SEM). We used analysis of variance to identify 
statistically significant differences among means. The non-parametric Spearman correlation 
test was used to compare breast cancer cells and control cell lines.  
 
124 
 
V. CONCLUSIONS AND FUTURE DIRECTIONS 
 
In conclusion, our results strongly support the presence in the basal-A BRCA1-mutated cell 
line HCC1937 of a BCSC subpopulation bearing the phenotype CD44
+
CD24
+
CD338
bright
, i.e. 
an antigenic combination different from the classical CD44
+
/CD24
-/low
.   
The nature of CD338
low
 and CD338
bright
 cells, expressing ABCG2 at different levels, remains 
to be clarified. Our results suggest that CD338
low
 could constitute the progeny of the most 
immature CD338
bright
. Particularly, CD338
low
 cells are likely to be the luminal progenitors 
blocked at this stage of development. This model would be in agreement with that proposed 
by Lim et al. who found an increased number of luminal progenitors in breast tissue from 
BRCA1 mutation carriers. Anyway, the nature of CD338
low
 and CD338
bright
 cells in HCC1937 
cell line, will be elucidated by their in vivo behavior through the analysis of tumors originated 
from the sorted cell subpopulation. To conclude that CD338 might constitute a novel antigen 
reliable to isolate BCSCs from basal-like breast cancers, our results should be extended to 
other BRCA1-mutated basal-like cell lines and to human tissues from patients with basal-like 
breast cancers.  
Considering this future perspective, concurrently to the study of breast cancer cell lines, a 
complementary work was carried out in the present thesis to standardize the flow-cytomertic 
methods to study patient-derived breast cancer cell cultures. This work will be subsequently 
used to isolate and study the putative CD44
+
CD24
+
CD338
bright
 BCSC population from human 
breast cancer tissues. While accomplishing this flow cytometry standardization work, we have 
also determined whether cell cultures established from human breast cancer tissues maintain 
the cellular heterogeneity of primary tissues and may therefore be used for in vitro modeling 
of breast cancer subtypes. With this work we confirmed that in vitro culturing of breast cancer 
125 
 
cells reduces luminal lineage-type of cells, displaying a basal/mesenchymal phenotype. 
Furthermore, we demonstrated that breast cancer cell cultures preserve inter-tumor 
heterogeneity and express stem/progenitor markers that can be identified, quantified and 
categorized by flow cytometry. 
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VI. FLOW CYTOMETRY APPENDIX 
 
6.1 Principles of Flow Cytometry 
Flow cytometry is a technology that measures multiple physical characteristics of single 
particles, usually cells. The properties measured include a particle’s relative size, relative 
granularity or internal complexit. A flow cytometer is made up of three main systems: 
fluidics, optics, and electronics. 
• The fluidics system transports particles in a stream to the laser beam for interrogation. 
• The optics system consists of lasers to illuminate the particles in the sample stream and 
optical filters to direct the resulting light signals to the appropriate detectors. 
• The electronics system converts the detected light signals into electronic signals that can be 
processed by the computer.  
When a sample is injected in a flow cytometer, cells are randomly distributed in the three-
dimensional space. For optimal illumination by lasers, the stream transporting the cells should 
be positioned in the center of the laser beam. In addition, only one cell or particle should 
move through the laser beam at a given moment. The sample must therefore be ordered into a 
stream of single cells. This process is managed by the fluidics system. Essentially, the fluidics 
system consists of a central core through which the sample is injected, enclosed by an outer 
sheath that contains faster flowing fluid. When the fluidic system is activated, the flow of 
sheath fluid accelerates the particles and restricts them to the center of the sample core. This 
effect, that creates a single file of cells, is called hydrodynamic focusing. Based on principles 
relating to laminar flow, the sample core remains separate but coaxial within the sheath fluid 
and does not mix with it (Figure 6.1). 
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After hydrodynamic focusing, each cell passes through one or more beams of light. Light 
scattering or fluorescence emission (if the cell is labeled with a fluorochrome) provides 
information about the cell’s properties. 
 
 
 
 
Figure 6.1: Hydrodynamic focus produces a single file of cells 
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The lasers are the most commonly used light sources in the modern flow cytometry. They 
produce a single wavelength of light at one or more frequencies. Light scattering occurs when 
a particle deflects incident laser light (Figure 6.2) . The extent to which this occurs depends 
on the physical properties of a particle. Forward-scattered light (FSC) is proportional to  cell 
surface area or size. FSC is a measurement of mostly diffracted light and is detected just off 
the axis of the incident laser beam in the forward direction by a photodiode, tipically up to 20° 
offset from the laser beam’s axis. Side-scattered light (SSC) is proportional to cell granularity 
or internal complexity. SSC is a measurement of mostly refracted and reflected light that 
occurs at any interface within the cell where there is a change in refractive index. Correlated 
measurements of FSC and SSC can allow for differentiation of cell types in a heterogeneous 
cell population just in function of their size and internal complexity. 
 
 
 
Figure 6.2: Light Scattering properties of a cell 
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In addition to its size and granularity, a particular cell type can be identified based on the 
individual antigenic surface markers by using a fluorescent dye conjugated to a monoclonal 
antibody. A fluorescent compound absorbs light energy over a range of wavelengths that is 
characteristic for that compound. This absorption of light causes an electron in the fluorescent 
compound to be raised to a higher energy level. The excited electron quickly decays to its 
ground state, emitting the excess energy as a photon of light. This transition of energy is 
called fluorescence. The range over which a fluorescent compound can be excited is termed 
its absorption spectrum. The range of emitted wavelengths for a particular compound is 
termed its emission spectrum. In summary, as cells intercept the light source they scatter light 
generating forward and side scatter light and fluorochromes are excited to a higher energy 
state. This energy is released as a photon of light with specific spectral properties unique to 
different fluorochromes antibody (Figure 6.3). So, In a mixed population of cells, different 
fluorochromes can be used to distinguish separate subpopulations and the amount of 
fluorescent signal detected is proportional to the number of fluorochrome molecules on the 
cell. So, the antibody staining pattern of each subpopulation, combined with FSC and SSC 
data, can be used to identify which cells are present in a sample and to count their relative 
percentages.  
 
 
 
 
 
 
 
Figure 6.3:  Fluorescent emission from fluorochrome-labeled cell surface molecules 
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The most useful fluorochromes for surface or intracellular epitope detection include single 
dyes and tandem dyes. Some of the single dyes, e.g. PE (figure 6.4), have been in use for the 
past 30 years but are now facing competition from alternatives like Alexa Fluor dyes which 
offer greater photostability and increased fluorescence. In a tandem dye, when the first dye is 
excited its energy is transferred To the second dye located in close proximity. This activates 
the second fluorochrome, which then produces the fluorescence emission. The process is 
called Fluorescence Resonance Energy Transfer (FRET). The majority of tandem dyes have 
been manufactured for the 488 nm laser which is found in most cytometers and they are very 
useful in multicolor fluorescences studies in combination with single dyes. 
 
 
 
Figure 6.4:  Absorpition and emission spectra of Phycoerithrin (PE) fluorochrome 
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The collections optics consist of a collection lens to collect light emitted from the particle–
laser beam interaction and a system of optical mirrors and filters to route specified 
wavelengths of the collected light to designated optical detectors. Light signals generated as 
particles pass through the laser beam signals are converted to electronic signals (voltages) by 
photodetectors and then assigned a channel number on a data plot. Detectors are either 
photodiodes or photomultipier tubes (PMTs). Photodiodes are usually used to measure 
forward scatter when the signal is strong. PMTs are more sensitive instruments and are ideal 
for scatter and fluorescence signals. The specificity of detection is controlled by optical 
filters, which block certain wavelengths while transmitting (passing) others. There are three 
major filter types. Long pass filters allow through light above a cut-off wavelength, short-pass 
permit light below a cut-off wavelength and band-pass transmit light within a specified 
narrow range of wavelengths. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5:  Schematic overview of optics system 
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6.2 Anaysis of data 
Once a data file has been saved, cell populations can be displayed in several different formats. 
A single parameter such as SSC or FITC (fluorescence1, FL1) can be displayed as a single 
parameter histogram, where the horizontal axis represents the parameter’s signal value in 
channel numbers and the vertical axis represents the number of events per channel number. 
Each event is placed in the channel that corresponds to its signal value. Signals with identical 
intensities accumulate in the same channel. Brighter signals are displayed in channels to the 
right of the dimmer signals. Two parameters can be displayed simultaneously in a dot plot 
(Fugure 6.6). One parameter is displayed on the x-axis and the other parameter is displayed 
on the y-axis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Examples of data representation: hystogram (left) and dot plot (right) 
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An important principle of flow cytometry data analysis is to selectively visualize the cells of 
interest (cells in which we want to analyze the expression of some markers) while eliminating 
results from unwanted particles, e.g. dead cells and debris. This procedure is called gating. A 
gate can be defined as a numerical or graphical boundary that can be used to define the 
characteristics of particles to include for further analysis. Cells are usually gated according to 
physical characteristics. For instance, subcellular debris and clumps can be distinguished from 
single cells by size, estimated by forward scatter. Also, dead cells have lower forward scatter 
and higher side scatter than living cells (Figure 6.7). 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Exclusion of dead cells according to physical parameters forward and side scatter 
 
After exclusion of debris, clumps and dead cells, it’s important to remove doublets from the 
subset of cells target of the analysis, because sometimes doublets can lead to false 
percentages. One of the most used method to discriminate single cells from doublets it’s the 
dot plot forward scatter-area (FSC-A) vs forward scatter-height (FSC-H) in which every 
events that are out of the diagonal are considered doublets because a doublet has the same 
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height value of a single cell but an higher area value. Cells passing through cytometer 
generate voltage pulses of characteristic shape, gaussian for round shaped cells (Figure 6.8). 
The ratio of area under the curve of the pulse to its width (x height) is different for single cells 
(Figure 6.8, upper left panel) and doublets (Figure 6.8, upper right panel)  due to the increase 
in time that light is scattered for when a doublet passes through compared to a singlet. In other 
words, doublets will have greater pulse width than a single cell, as they take longer to pass 
through the laser beam. 
 
 
Figure 6.8: Exclusion of doublets according to physical parameters forward-area (FSC-A) 
and forward-height scatter (FSC-H). 
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Once debris, dead cells and doublets have been excluded with gates on phisical parameter dot 
plots, the gated cell subset can be further analyzed to evaluate the expression of cell surface 
markers using fluorescent signals emitted by the fluorochrome-conjugated antidodies bound 
to the cell membrane. Generally, the expression of surface markers can be evaluated using 
two different approaches. The most common consists to define the percentage of cells which 
are positive for the marker indicating how many cells express (positive) and not express 
(negative) that marker in the target cell population. The percentage of positive cells is 
established by using a negative control. Generally, in flow cytometry analysis two kinds of 
negative controls are important: 1)  the isotypic control, that allows to show aspecific 
bindings between the Igs and the cellular membrane; 2) the unstained cells, that allow to show 
the autofluorescence of cells. More particularly, the isotypic control is essential only when the 
analyzed cells express the receptor for the Fc fragment of Ig. Moreover, in multicolor flow 
cytometry analysis, when the expression of a high number of antigens is analyzed at the same 
time, it is usual to find some antigens expressed (positive) and others that are not expressed 
(negative). This allows to have many internal negative controls that can be considered 
"isotypic". In other words, the negative antigens can be used as controls for the positive ones. 
The percentage is very useful when the sample analyzed is heterogeneous including different 
types of cells that can or cannot express that marker. In addition to the percentage, the 
expression of surface markers can be also evaluated by fluorescence intensity that is 
proportional to the number of antibodies bound to the membrane and so to the number of 
recognized molecules present on the cell membrane. The fluorescence intensity gives an 
information different from that given by the percentage: it indicates the level of expression of 
a molecule on a particular cell type. So, the percentage can be used to identify different cell 
types in the sample analyzed and the fluorescence intensity to define the expression level of 
many molecules on each cell type. 
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6.3  Cell Sorting  
In most applications, after a particle exits the laser beam, it is sent to waste. Sorting allows to 
capture and collect cells of interest for further analysis. Once collected, the cells can be 
analyzed microscopically, biochemically, or functionally. To sort particles or cells, the 
cytometer first needs to identify the cells of interest, then separate out the individual cells. 
Once the population of interest has been identified on a data acquisition plot, a gate is drawn 
around that population. This gate is then loaded into the cytometer’s software as the “sort 
gate” that identifies cells of interest to be sorted out of the stream. In particular, in order to 
sort the fluid stream containing cells must be precisely, and reproducibly over a substantial 
time frame, broken into drops. To this aim, during sorting drop drive energy is applied to the 
stream through a vibrating nozzle to break it into highly uniform droplets. In particular, the 
nozzle is vibrated by a transducer which converts electrical energy into mechanical energy 
Droplets detach from the stream a few millimeters downstream from the nozzle. When a 
particle is detected that meets the predefined sorting criteria, an electrical charge is applied to 
the stream just as the droplet containing that particle breaks off from the stream. Once broken 
off from the stream, the drople still retains its charge. The charged droplet passes by two 
strongly charged deflection plates. Electrostatic attraction and repulsion cause each charged 
droplet to be deflected to the left or right, depending on the droplet’s charge polarity. 
Uncharged droplets are not affected by the electric field and pass down the center to the waste 
aspirator (Figure 6.9). 
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Figure 6.9: Schematic representation of cell sorting 
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6.4  Cytometers used in the study 
During this study different types of cytometers have been used. The most part of analysis and 
cell sorting were performed with FACSAria I cell sorter (Becton Dickinson, Franklin Lakes, 
NJ).  The BD FACSAria instrument uses low-powered air-cooled and solid-state lasers that 
do not have special power and cooling requirements. The instrument is equipped with  three 
lasers: 488-nm blue laser, 633-nm, red laser and 407-nm violet laser. Moreover, the 375nm 
near UV optional laser has been installed. The 375-nm laser and the violet laser share the 
same beam spot at the point of interception within the cuvette, so I had to select to run either 
the 375- nm laser, or the violet laser.   
To analyze the expression of CD338 and to sort out the different CD338 subpopulations from 
HCC1937 cell line, a PE conjugated antibody has been used in the present study. PE 
fluorescence of CD338 was determined by a 488nm excitation line (blue laser) and detected 
by 585/42 nm filters (Table 13).  The 488 nm laser allowed to discriminate CD338 positive 
cells from CD338 negative cells.  
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Table 13: Default setup for detector array in FACSAria I cell sorter. In red are underlined 
the laser and the filter used to respectively excite and detect the PE fluorochrome conjugated 
to the CD338 antibody. 
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Later, I had the opportunity to sort the different CD338 subpopulations with FACSAria III 
cell sorter that is equipped with five lasers: 488nm, 561nm, 640nm, 405nm, 355nm. The 
561nm yellow-green laser is a better laser than 488 blue laser to excite PE. It allows to better 
discriminate the different fluorescence intensities emitted by PE fluorochrome. So, I 
performed some cell sorting of CD338 negative and positive cells by using the yellow-green 
laser, but the purity of cell sorting was very low (about 20%) (Figure 6.10). I carried out many 
cytometric tests to understand if such a low purity was due to the cells, the antibody, the 
fluorochrome or the cyometer and finally I found that there was a problem just with the 
yellow-green laser of FACSARIA III cell sorter. So, despite the yellow-green laser is the best 
laser to excite PE, unfortunately I could not use it with FACSAria III cell sorter and I had to 
come back to use the blue laser of FACSAria I to sort CD338 populations out of HCC1937 
cell line.  
 
 
 
 
 
 
 
 
 
Figure 6.10: Purity of cell sorting performed with 561 nm green laser of FACSAria III 
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However, I could use the same 561nm yellow-green laser of another well-working cytometer, 
LSR II. Unfortunately, LSR II is not a cell sorter but just an analyzer, so I could not use it to 
sort HCC1937 cells but just to analyze them. In particular I used it: 1) to discriminate, among 
the CD338 negative cells, the real negative cells from a subpopulation of cells expressing 
CD338 at low level, named CD338
+/low 
(Figure 6.11, upper right panel); 2) to check the purity 
of cell sorting performed with FACSAria I; 3) to follow the expression of CD338 in cultured 
sorted cells. In particular, with LSR II cytometer I could analyze the expression of CD338  
with both lasers, 488nm and 561nm, at the same time. The comparison of data obtained with 
the two lasers, allowed me to have a clear view on the real expression of CD338 in HCC1937 
cell line and on the nature of sorted cell subpopulations. Moreover this comparison allowed 
me to try to sort the three CD338 subpopulations, CD338
+/bright
 CD338
+/low
 and CD338
neg
, 
with the blue laser of FACSAria I, on the base of the two images given by the blue and the 
yellow-green lasers of LSR II cytometer (Figure 6.11). 
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Figure 6.11. Expression of CD338 in HCC1937 cell line and cell sorting of three cell 
subsets.  Upper panels: FACSAria I Cytometer is equipped with the blue laser that is able to 
discriminate just CD338 positive (upper left panel, red events) and CD338 negative (upper 
left panel, blue and yellow events). LSR II Cytometer is equipperd also with the yellow-green 
laser that is able to discriminate three different cell subsets: bright, low and negative cells 
(upper right panel). Blue events, that seemed to be CD338 negative cells according to the blue 
laser, actually are CD338 positive (as shown by the yellow laser), although expressing CD338 
at lower level than CD338
bright
 cells. Lower panels: example of sorting of the three subsets 
performed with FACAria I sorter on the base of the images given by the two lasers of  LSR II 
analyzer.  
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